Em P Richard Clark MA, MD, MRCP, FRCPath

Professor of Haematology Molecular & Clinical Cancer Medicine

+44 (0)151 706 4323 / +44 (0)151 794 9818
Work email R.E.Clark@liverpool.ac.uk

Publications

Filter the publication list

Filter list by type

Show all
Journal article
Conference paper
Chapter
Other

2023

Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management (Journal article)

Milojkovic, D., Lyon, A. R., Mehta, P., Dimitriadou, E., Choudhuri, S., Manisty, C., . . . Clark, R. E. (2023). Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management. EUROPEAN JOURNAL OF HAEMATOLOGY, 111(2), 201-210. doi:10.1111/ejh.13983

DOI: 10.1111/ejh.13983

Generic imatinib: Data from the UK National Registry for chronic myeloid leukaemia patients (Conference Paper)

Nesr, G., Braithwaite, B., Mathew, P., Hashmi, M., Claudiani, S., Milojkovic, D., . . . Clark, R. E. (2023). Generic imatinib: Data from the UK National Registry for chronic myeloid leukaemia patients. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 201 (pp. 92-93). Retrieved from https://www.webofscience.com/

2022

Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation (Journal article)

Karg, E., Baldow, C., Zerjatke, T., Clark, R. E., Roeder, I., Fassoni, A. C., & Glauche, I. (2022). Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation. FRONTIERS IN ONCOLOGY, 12. doi:10.3389/fonc.2022.1028871

DOI: 10.3389/fonc.2022.1028871

Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study (Conference Paper)

Dominy, K., Salmon, M., Szydlo, R., Hayden, C., White, H. E., Alikian, M., . . . Apperley, J. F. (2022). Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study. In BLOOD Vol. 140 (pp. 9631-9632). doi:10.1182/blood-2022-170375

DOI: 10.1182/blood-2022-170375

Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation (Preprint)

DOI: 10.21203/rs.3.rs-1917622/v1

A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands (Journal article)

Claudiani, S., Janssen, J. J. W. M., Byrne, J., Smith, G., Blijlevens, N., Raghavan, M., . . . Apperley, J. F. (2022). A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands. EUROPEAN JOURNAL OF HAEMATOLOGY, 109(1), 90-99. doi:10.1111/ejh.13775

DOI: 10.1111/ejh.13775

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial (Conference Paper)

Brummendorf, T. H., Cortes, J. E., Milojkovic, D., Gambacorti-Passerini, C., Clark, R. E., le Coutre, P., . . . Deininger, M. W. (2022). Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial. In LEUKEMIA Vol. 36 (pp. 1825-1833). doi:10.1038/s41375-022-01589-y

DOI: 10.1038/s41375-022-01589-y

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial (Journal article)

Russell, N. H., Hills, R. K., Thomas, A., Thomas, I., Kjeldsen, L., Dennis, M., . . . Burnett, A. K. (2022). Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. HAEMATOLOGICA, 107(7), 1518-1527. doi:10.3324/haematol.2021.279010

DOI: 10.3324/haematol.2021.279010

A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial (Journal article)

Russell, N. H., Hills, R. K., Kjeldsen, L., Clark, R. E., Ali, S., Cahalin, P., . . . Burnett, A. K. (2022). A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial. BRITISH JOURNAL OF HAEMATOLOGY. doi:10.1111/bjh.18195

DOI: 10.1111/bjh.18195

The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia (Journal article)

Gallipoli, P., Clark, R. E., Byrne, J., Apperley, J. F., Milojkovic, D., Foroni, L., . . . O'Brien, S. (2022). The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 196(6), E55-E57. doi:10.1111/bjh.17961

DOI: 10.1111/bjh.17961

Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial (Journal article)

Copland, M., Slade, D., McIlroy, G., Horne, G., Byrne, J. L., Rothwell, K., . . . Yap, C. (2022). Ponatinib with fludarabine, cytarabine, idarubicin, and granulocyte colony-stimulating factor chemotherapy for patients with blast-phase chronic myeloid leukaemia (MATCHPOINT): a single-arm, multicentre, phase 1/2 trial. LANCET HAEMATOLOGY, 9(2), E121-E132. doi:10.1016/S2352-3026(21)00370-7

DOI: 10.1016/S2352-3026(21)00370-7

2021

Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients (Journal article)

Dennis, M., Thomas, I. F., Ariti, C., Upton, L., Burnett, A. K., Gilkes, A., . . . Grp, U. K. N. C. R. I. A. M. L. W. (2021). Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. BLOOD ADVANCES, 5(24), 5621-5625. doi:10.1182/bloodadvances.2021005038

DOI: 10.1182/bloodadvances.2021005038

A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial (Journal article)

Dennis, M., Burnett, A., Hills, R., Thomas, I., Ariti, C., Severinsen, M. T., . . . Russell, N. (2021). A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial. BRITISH JOURNAL OF HAEMATOLOGY, 194(2), 298-308. doi:10.1111/bjh.17501

DOI: 10.1111/bjh.17501

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (vol 35, 20-LEU-1554R, 2021) (Journal article)

Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D. -W., Issaragrisil, S., le Coutre, P., . . . Hochhaus, A. (2021). Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (vol 35, 20-LEU-1554R, 2021). LEUKEMIA, 35(7), 2142-2143. doi:10.1038/s41375-021-01306-1

DOI: 10.1038/s41375-021-01306-1

Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (Journal article)

Makela, E., Pavic, K., Varila, T., Salmenniemi, U., Loyttyniemi, E., Nagelli, S. G., . . . Westermarck, J. (2021). Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias. CLINICAL CANCER RESEARCH, 27(10), 2848-2860. doi:10.1158/1078-0432.CCR-20-3679

DOI: 10.1158/1078-0432.CCR-20-3679

Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia (Journal article)

Clark, R. E., Basabrain, A. A., Austin, G. M., Holcroft, A. K., Loaiza, S., Apperley, J. F., . . . Lucas, C. M. (2021). Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia. CANCERS, 13(9). doi:10.3390/cancers13092155

DOI: 10.3390/cancers13092155

Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression (Journal article)

Clark, R. E., Apperley, J. F., Copland, M., & Cicconi, S. (2021). Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. BLOOD ADVANCES, 5(4), 1102-1109. doi:10.1182/bloodadvances.2020003570

DOI: 10.1182/bloodadvances.2020003570

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis (Journal article)

Kantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D. -W., Issaragrisil, S., le Coutre, P., . . . Hochhaus, A. (n.d.). Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. doi:10.1038/s41375-020-01111-2

DOI: 10.1038/s41375-020-01111-2

Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study (Journal article)

Milojkovic, D., Cross, N. C. P., Ali, S., Byrne, J., Campbell, G., Dignan, F. L., . . . Mead, A. J. (2021). Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. BRITISH JOURNAL OF HAEMATOLOGY, 192(1), 62-74. doi:10.1111/bjh.16733

DOI: 10.1111/bjh.16733

2020

Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses. (Journal article)

Burnett, A. K., Russell, N. H., Hills, R. K., Knapper, S., Freeman, S., Huntly, B., . . . Spearing, R. (2020). Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, JCO2001170. doi:10.1200/jco.20.01170

DOI: 10.1200/jco.20.01170

Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review (Journal article)

Cortes, J. E., Candoni, A., Clark, R. E., Leber, B., Montesinos, P., Vyas, P., . . . Heuser, M. (2020). Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. Leukemia and Lymphoma, 61(14), 3287-3305. doi:10.1080/10428194.2020.1817445

DOI: 10.1080/10428194.2020.1817445

The chronic myeloid leukaemia story in the United Kingdom since 1960 (Journal article)

Clark, R. E. (2020). The chronic myeloid leukaemia story in the United Kingdom since 1960. BRITISH JOURNAL OF HAEMATOLOGY, 191(4), 521-526. doi:10.1111/bjh.17149

DOI: 10.1111/bjh.17149

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia (Journal article)

Pfirrmann, M., Clark, R. E., Prejzner, W., Lauseker, M., Baccarani, M., Saussele, S., . . . Hoffmann, V. S. (2020). The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. LEUKEMIA, 34(8), 2138-2149. doi:10.1038/s41375-020-0931-9

DOI: 10.1038/s41375-020-0931-9

Another set of guidelines for chronic myeloid leukaemia (Journal article)

Clark, R. E. (2020). Another set of guidelines for chronic myeloid leukaemia. British Journal of Haematology. doi:10.1111/bjh.16970

DOI: 10.1111/bjh.16970

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease (Journal article)

Horne, G. A., Stobo, J., Kelly, C., Mukhopadhyay, A., Latif, A. L., Dixon-Hughes, J., . . . Copland, M. (2020). A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease. LEUKEMIA, 34(7), 1775-1786. doi:10.1038/s41375-019-0700-9

DOI: 10.1038/s41375-019-0700-9

Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. (Journal article)

Kinstrie, R., Horne, G. A., Morrison, H., Irvine, D., Munje, C., Castañeda, E. G., . . . Copland, M. (2020). Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.. Leukemia, 34(7), 1975. doi:10.1038/s41375-020-0721-4

DOI: 10.1038/s41375-020-0721-4

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy (Journal article)

Kinstrie, R., Horne, G. A., Morrison, H., Irvine, D., Munje, C., Castaneda, E. G., . . . Copland, M. (2020). CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. LEUKEMIA, 34(6), 1613-1625. doi:10.1038/s41375-019-0684-5

DOI: 10.1038/s41375-019-0684-5

Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients. (Journal article)

Davies, A., Rodriguez-Vicente, A. E., Austin, G., Loaiza, S., Foroni, L., Clark, R. E., & Pirmohamed, M. (2020). Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients.. Scientific reports, 10(1). doi:10.1038/s41598-020-65350-0

DOI: 10.1038/s41598-020-65350-0

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (Journal article)

Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., . . . Hehlmann, R. (2020). European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. LEUKEMIA, 34(4), 966-984. doi:10.1038/s41375-020-0776-2

DOI: 10.1038/s41375-020-0776-2

Molecular dynamics during reduction of TKI dose reliably identify molecular recurrence after treatment cessation in CML. (Journal article)

Gottschalk, A., Glauche, I., Cicconi, S., Clark, R. E., & Roeder, I. (2020). Molecular dynamics during reduction of TKI dose reliably identify molecular recurrence after treatment cessation in CML.. Blood. doi:10.1182/blood.2019003395

DOI: 10.1182/blood.2019003395

Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia. (Journal article)

Schmidt, T., Kharabi Masouleh, B., Loges, S., Cauwenberghs, S., Fraisl, P., Maes, C., . . . Carmeliet, P. (2020). Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia.. Cancer cell, 37(1), 135-136. doi:10.1016/j.ccell.2019.12.010

DOI: 10.1016/j.ccell.2019.12.010

2019

Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice (Journal article)

Clark, R. E. (2019). Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 14(6), 507-514. doi:10.1007/s11899-019-00548-2

DOI: 10.1007/s11899-019-00548-2

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML) (Journal article)

Claudiani, S., Metelli, S., Kamvar, R., Szydlo, R., Khan, A., Byrne, J., . . . Apperley, J. F. (2019). Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML). BLOOD, 134. doi:10.1182/blood-2019-131500

DOI: 10.1182/blood-2019-131500

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis (Conference Paper)

Hughes, T. P., Saglio, G., Larson, R. A., Kantarjian, H. M., Kim, D. -W., Issaragrisil, S., . . . Hochhaus, A. (2019). Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis. In BLOOD Vol. 134. doi:10.1182/blood-2019-128761

DOI: 10.1182/blood-2019-128761

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin (Journal article)

Lauseker, M., Bachl, K., Turkina, A., Faber, E., Prejzner, W., Olsson-Stromberg, U., . . . Pfirrmann, M. (2019). Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin. AMERICAN JOURNAL OF HEMATOLOGY, 94(11), 1236-1243. doi:10.1002/ajh.25628

DOI: 10.1002/ajh.25628

Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5′ AMP-activated protein kinase signalling in malignant cells (Journal article)

Austin, J. A., Jenkins, R. E., Austin, G. M., Glenn, M. A., Dunn, K., Scott, L., . . . Clark, R. E. (2019). Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5′ AMP-activated protein kinase signalling in malignant cells. BIOCHEMICAL JOURNAL, 476, 2255-2269. doi:10.1042/BCJ20190121

DOI: 10.1042/BCJ20190121

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial (Journal article)

Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Rothwell, K., Pocock, C., . . . Copland, M. (2019). De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. The Lancet Haematology, 6(7), E375-E383. doi:10.1016/S2352-3026(19)30094-8

DOI: 10.1016/S2352-3026(19)30094-8

Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts (Journal article)

Sadiq, S., Owen, E., Foster, T., Knight, K., Wang, L., Pirmohamed, M., . . . Pushpakom, S. (2019). Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts. Leukemia, 33, 1810-1814. doi:10.1038/s41375-018-0337-0

DOI: 10.1038/s41375-018-0337-0

The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial (Journal article)

Austin, G. M., Knight, K., Bell, J., Carter, A., Heartin, E., Watson, D., . . . Clark, R. E. (2019). The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial. BRITISH JOURNAL OF HAEMATOLOGY, 185(4), 791-793. doi:10.1111/bjh.15629

DOI: 10.1111/bjh.15629

Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial. (Conference Paper)

Cortes, J. E., Brummendorf, T. H., Gambacorti-Passerini, C., Clark, R. E., Leip, E., Viqueira, A., . . . Deininger, M. W. N. (2019). Cardiac, vascular, and hypertension safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37. Retrieved from https://www.webofscience.com/

Long-term survival of CML patients who received autologous HCT before and after the tyrosine kinase inhibitors ERA. Study on behalf of the EBMT CMWP (Conference Paper)

Michallet, M., Sobh, M., Hazelaar, S., Apperley, J., Milpied, N., Labussiere-Wallet, H., . . . Yakoub-Agha, I. (2019). Long-term survival of CML patients who received autologous HCT before and after the tyrosine kinase inhibitors ERA. Study on behalf of the EBMT CMWP. In BONE MARROW TRANSPLANTATION Vol. 54 (pp. 201-202). Retrieved from https://www.webofscience.com/

2018

Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial (Journal article)

Burnett, A. K., Das Gupta, E., Knapper, S., Khwaja, A., Sweeney, M., Kjeldsen, L., . . . Russel, N. H. (2018). Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial. HAEMATOLOGICA, 103(10), 1654-1661. doi:10.3324/haematol.2018.189514

DOI: 10.3324/haematol.2018.189514

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial. (Journal article)

Russell, N., Burnett, A., Hills, R., Betteridge, S., Dennis, M., Jovanovic, J., . . . NCRI AML Working Group. (2018). Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial.. Blood, 132(13), 1452-1454. doi:10.1182/blood-2018-05-851824

DOI: 10.1182/blood-2018-05-851824

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML (Journal article)

Lucas, C. M., Scott, L. J., Carmell, N., Holcroft, A. K., Hills, R. K., Burnett, A. K., & Clark, R. E. (2018). CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML. Blood Advances, 2(9), 964-968. doi:10.1182/bloodadvances.2017013615

DOI: 10.1182/bloodadvances.2017013615

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition (Journal article)

Mitchell, R., Hopcroft, L. E. M., Baquero, P., Allan, E. K., Hewit, K., James, D., . . . Helgason, G. V. (2018). Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 110(5), 467-478. doi:10.1093/jnci/djx236

DOI: 10.1093/jnci/djx236

De-escalation and discontinuation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia (CML) in stable major molecular response: 2-year data from the British DESTINY study (Conference Paper)

Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Pocock, C., Smith, G., . . . Copland, M. (2018). De-escalation and discontinuation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia (CML) in stable major molecular response: 2-year data from the British DESTINY study. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 6). Retrieved from https://www.webofscience.com/

Efficacy and Safety of First-Line Bosutinib versus Imatinib in the BFORE trial: 18-Month Follow-up (Conference Paper)

Clark, R. E., Gambacorti-Passerini, C., Deininger, M., Mauro, M. J., Chuah, C., Kim, D. -W., . . . Cortes, J. E. (2018). Efficacy and Safety of First-Line Bosutinib versus Imatinib in the BFORE trial: 18-Month Follow-up. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 7-8). Retrieved from https://www.webofscience.com/

First report from the UK National Registry for chronic myeloid leukaemia: Analysis of baseline characteristics of 435 patients (Conference Paper)

Nesr, G. N. G., Szydlo, R., Braithwaite, B., Frackleton, S., Apperley, J., Milojkovic, D., . . . Clark, R. E. (2018). First report from the UK National Registry for chronic myeloid leukaemia: Analysis of baseline characteristics of 435 patients. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 48). Retrieved from https://www.webofscience.com/

In chronic myeloid leukaemia cells, the oncoprotein CIP2A binds directly to and alters expression of many cellular proteins, independent of effects on protein phosphatase 2A (PP2A) (Conference Paper)

Austin, J. A., Lucas, C. M., Jenkins, R. E., Dunn, K., Scott, L. J., Glenn, M. A., . . . Clark, R. E. (2018). In chronic myeloid leukaemia cells, the oncoprotein CIP2A binds directly to and alters expression of many cellular proteins, independent of effects on protein phosphatase 2A (PP2A). In BRITISH JOURNAL OF HAEMATOLOGY Vol. 181 (pp. 52-53). Retrieved from https://www.webofscience.com/

Snížení terapeutické dávky TKI před kompletním vysazením léčby zlepšuje šanci na úspěšné zastavení léčby u pacientů s chronickou myeloidní leukemií (CML): dvouleté výsledky britské studie DESTINY (Journal article)

Clark, R., Polydoros, F., Apperley, J., & Koblihová, P. J. (2018). Snížení terapeutické dávky TKI před kompletním vysazením léčby zlepšuje šanci na úspěšné zastavení léčby u pacientů s chronickou myeloidní leukemií (CML): dvouleté výsledky britské studie DESTINY. Transfuze a Hematologie Dnes, 24(1), 60.

2017

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy (Journal article)

Claudiani, S., Apperley, J. F., Gale, R. P., Clark, R., Szydlo, R., Deplano, S., . . . Milojkovic, D. (2017). E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.. Haematologica, 102(8), e297-e299. doi:10.3324/haematol.2017.168740

DOI: 10.3324/haematol.2017.168740

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial (Journal article)

Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Pocock, C., Smith, G., . . . Copland, M. (2017). De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. The Lancet Haematology, 4(7), E310-E316. doi:10.1016/S2352-3026(17)30066-2

DOI: 10.1016/S2352-3026(17)30066-2

NILOTINIB-INDUCED METABOLIC DYSFUNCTION: INSIGHTS FROM A TRANSLATIONAL PILOT STUDY USING IN VITRO ADIPOCYTE MODELS AND PATIENT COHORTS (Poster)

Sadiq, S., Owen, E., Foster, T., Knight, K., Wang, L., Pirmohamed, M., . . . Pushpakom, S. (2017). NILOTINIB-INDUCED METABOLIC DYSFUNCTION: INSIGHTS FROM A TRANSLATIONAL PILOT STUDY USING IN VITRO ADIPOCYTE MODELS AND PATIENT COHORTS. Poster session presented at the meeting of Unknown Conference. Retrieved from https://www.webofscience.com/

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia (Journal article)

Ben-Batalla, I., Erdmann, R., Jorgensen, H., Mitchell, R., Ernst, T., Von Amsberg, G., . . . Loges, S. (2017). Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia. CLINICAL CANCER RESEARCH, 23(9), 2289-2300. doi:10.1158/1078-0432.CCR-16-1930

DOI: 10.1158/1078-0432.CCR-16-1930

Cardiologist's perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Reply (Journal article)

Steegmann, J. L., Baccarani, M., & Clark, R. E. (2017). Cardiologist's perspective to the European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Reply. LEUKEMIA, 31(3), 772-773. doi:10.1038/leu.2016.337

DOI: 10.1038/leu.2016.337

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. (Journal article)

Hoffmann, V. S., Baccarani, M., Hasford, J., Castagnetti, F., Di Raimondo, F., Casado, L. F., . . . Hehlmann, R. (2017). Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.. Leukemia, 31(3), 593-601. doi:10.1038/leu.2016.246

DOI: 10.1038/leu.2016.246

A comparison of clofarabine with Ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia. (Journal article)

Burnett, A. K., Russell, N. H., Hills, R. K., Kell, J., Nielsen, O. J., Dennis, M., . . . Clark, R. E. (2017). A comparison of clofarabine with Ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.. Leukemia, 31, 310-317. doi:10.1038/leu.2016.225

DOI: 10.1038/leu.2016.225

2016

Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia (Journal article)

Kinstrie, R., Karamitros, D., Goardon, N., Morrison, H., Hamblin, M., Robinson, L., . . . Vyas, P. (2016). Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia. BLOOD ADVANCES, 1(3), 160-169. doi:10.1182/bloodadvances.2016000810

DOI: 10.1182/bloodadvances.2016000810

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study (Conference Paper)

Clark, R. E., Polydoros, F., Apperley, J. F., Pocock, C., Smith, G., Byrne, J. L., . . . Copland, M. (2016). Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.938.938

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation (Journal article)

Ferguson, P., Hills, R. K., Grech, A., Betteridge, S., Kjeldsen, L., Dennis, M., . . . Craddock, C. (2016). An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. HAEMATOLOGICA, 101(11), 1351-1358. doi:10.3324/haematol.2016.148825

DOI: 10.3324/haematol.2016.148825

Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial (Journal article)

Martin, A. P., Richards, S., Haycox, A., Houten, R., McLeod, C., Braithwaite, B., . . . Clark, R. E. (2016). Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial. JOURNAL OF CLINICAL APHERESIS, 31(5), 434-442. doi:10.1002/jca.21433

DOI: 10.1002/jca.21433

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia (Journal article)

Steegmann, J. L., Baccarani, M., Breccia, M., Casado, L. F., Garcia-Gutierrez, V., Hochhaus, A., . . . Clark, R. E. (2016). European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. LEUKEMIA, 30(8), 1648-1671. doi:10.1038/leu.2016.104

DOI: 10.1038/leu.2016.104

CLONAL STRUCTURES OF LEUKAEMIA STEM CELL POPULATIONS IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKAEMIA (Conference Paper)

Karamitros, D., Morrison, H., Kinstrie, R., Goardon, N., Clark, R. E., Copland, M., & Vyas, P. (2016). CLONAL STRUCTURES OF LEUKAEMIA STEM CELL POPULATIONS IN MYELOID BLAST PHASE CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 101 (pp. 234-235). Retrieved from https://www.webofscience.com/

THE ADVERSE EFFECTS OF CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A, ARE LINKED WITH REDUCTION OF FUNCTIONAL B56GAMMA, A REGULATORY SUBUNIT OF PROTEIN PHOSPHATASE 2A, IN CHRONIC MYELOID LEUKAEMIA (Conference Paper)

Austin, J. A., Lucas, C. M., Scott, L., Holcroft, A., Wang, L., & Clark, R. E. (2016). THE ADVERSE EFFECTS OF CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A, ARE LINKED WITH REDUCTION OF FUNCTIONAL B56GAMMA, A REGULATORY SUBUNIT OF PROTEIN PHOSPHATASE 2A, IN CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 101 (pp. 182). Retrieved from https://www.webofscience.com/

High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-X-L in chronic myeloid leukemia (Journal article)

Lucas, C. M., Milani, M., Butterworth, M., Carmell, N., Scott, L. J., Clark, R. E., . . . Varadarajan, S. (2016). High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-X-L in chronic myeloid leukemia. LEUKEMIA, 30(6), 1273-1281. doi:10.1038/leu.2016.42

DOI: 10.1038/leu.2016.42

Defining The Dose Of Gemtuzumab Ozogamicin In Combination With Induction Chemotherapy In Acute Myeloid Leukemia: A Comparison Of 3 Mg/M2 With 6 Mg/M2 In The NCRI AML17 Trial (Journal article)

Burnett, A., Cavenagh, J., Russell, N., Hills, R., Kell, J., Jones, G., . . . Grp, U. K. N. C. R. I. A. M. L. S. (2016). Defining The Dose Of Gemtuzumab Ozogamicin In Combination With Induction Chemotherapy In Acute Myeloid Leukemia: A Comparison Of 3 Mg/M2 With 6 Mg/M2 In The NCRI AML17 Trial. Haematologica: the hematology journal, 101(6), 724-731. doi:10.3324/haematol.2016.141937

DOI: 10.3324/haematol.2016.141937

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial (Journal article)

Hochhaus, A., Saglio, G., Hughes, T. P., Larson, R. A., Kim, D. -W., Issaragrisil, S., . . . Kantarjian, H. M. (2016). Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. LEUKEMIA, 30(5), 1044-1054. doi:10.1038/leu.2016.5

DOI: 10.1038/leu.2016.5

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial (Journal article)

Lipton, J. H., Chuah, C., Guerci-Bresler, A., Rosti, G., Simpson, D., Assouline, S., . . . Investigators, E. P. I. C. (2016). Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. The Lancet Oncology, 17(5), 612-621. doi:10.1016/S1470-2045(16)00080-2

DOI: 10.1016/S1470-2045(16)00080-2

De-escalation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia patients with excellent molecular responses: Initial safety results from the DESTINY trial (Conference Paper)

Clark, R. E., Polydoros, F., Apperley, J. F., Pocock, C., Smith, G., Salim, R., . . . Copland, M. (2016). De-escalation of tyrosine kinase inhibitor treatment in chronic myeloid leukaemia patients with excellent molecular responses: Initial safety results from the DESTINY trial. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 173 (pp. 12). Retrieved from https://www.webofscience.com/

T cell subsets do not alter on decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: Data from the DESTINY trial (Conference Paper)

Austin, G., Knight, K., Bell, J., Foroni, L., Salim, R., Christmas, S. E., . . . Clark, R. E. (2016). T cell subsets do not alter on decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: Data from the DESTINY trial. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 173 (pp. 119). Retrieved from https://www.webofscience.com/

The Cdk2 inhibitor, Purvalanol A, induces apoptosis is myeloid cells via p38-MAPK dependent turnover of Mcl-1 (Conference Paper)

Phoomvuthisarn, P., Wright, H. L., Clark, R. E., Mutirangura, A., & Edwards, S. W. (2016). The Cdk2 inhibitor, Purvalanol A, induces apoptosis is myeloid cells via p38-MAPK dependent turnover of Mcl-1. In EUROPEAN JOURNAL OF CLINICAL INVESTIGATION Vol. 46 (pp. 81). Retrieved from https://www.webofscience.com/

2015

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy (Conference Paper)

Ferguson, P., Hills, R. K., Grech, A., Betteridge, S., Kjeldsen, L., Dennis, M., . . . Craddock, C. (2015). An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy. In BLOOD Vol. 126. doi:10.1182/blood.V126.23.559.559

DOI: 10.1182/blood.V126.23.559.559

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial (Journal article)

Burnett, A. K., Russell, N. H., Hills, R. K., Bowen, D., Kell, J., Knapper, S., . . . Grimwade, D. (2015). Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet Oncology, 16(13), 1295-1305. doi:10.1016/S1470-2045(15)00193-X

DOI: 10.1016/S1470-2045(15)00193-X

A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia (Journal article)

Russell, N. H., Kjeldsen, L., Craddock, C., Pagliuca, A., Yin, J. A., Clark, R. E., . . . Burnett, A. K. (2015). A comparative assessment of the curative potential of reduced intensity allografts in acute myeloid leukaemia. LEUKEMIA, 29(7), 1478-1484. doi:10.1038/leu.2014.319

DOI: 10.1038/leu.2014.319

Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients (Journal article)

Lucas, C., Harris, B., Holcroft, A., Scott, L., Carmell, N., McDonald, E., . . . Clark, R. (2015). Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients. Leukemia, 29(7), 1514-1523. doi:10.1038/leu.2015.71

DOI: 10.1038/leu.2015.71

Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial (Journal article)

Mead, A. J., Milojkovic, D., Knapper, S., Garg, M., Chacko, J., Farquharson, M., . . . Harrison, C. (2015). Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. BRITISH JOURNAL OF HAEMATOLOGY, 170(1), 29-39. doi:10.1111/bjh.13379

DOI: 10.1111/bjh.13379

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients (Journal article)

Burnett, A. K., Russell, N. H., Hills, R. K., Kell, J., Cavenagh, J., Kjeldsen, L., . . . Clark, R. (2015). A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients. Blood, 125(25), 3878-3885. doi:10.1182/blood-2015-01-623447

DOI: 10.1182/blood-2015-01-623447

A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia (Journal article)

Burnett, A. K., Russell, N., Hills, R. K., Panoskaltsis, N., Khwaja, A., Hemmaway, C., . . . Milligan, D. (2015). A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. Leukemia, 29(6), 1312-1319. doi:10.1038/leu.2015.38

DOI: 10.1038/leu.2015.38

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries (Journal article)

Hoffmann, V. S., Baccarani, M., Hasford, J., Lindoerfer, D., Burgstaller, S., Sertic, D., . . . Hehlmann, R. (2015). The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. LEUKEMIA, 29(6), 1336-1343. doi:10.1038/leu.2015.73

DOI: 10.1038/leu.2015.73

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia (Journal article)

Dennis, M., Russell, N., Hills, R. K., Hemmaway, C., Panoskaltsis, N., McMullin, M. -F., . . . Burnett, A. K. (2015). Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia. BLOOD, 125(19), 2923-2932. doi:10.1182/blood-2014-10-608117

DOI: 10.1182/blood-2014-10-608117

C-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia (Journal article)

Lucas, C., Harris, B., Giannoudis, A., & Clark, R. (2015). C-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia. Haematologica, 100(05), e179-e182. doi:10.3324/haematol.2014.115691

DOI: 10.3324/haematol.2014.115691

Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP) (Journal article)

Snarski, E., Snowden, J. A., Oliveira, M. C., Simoes, B., Badoglio, M., Carlson, K., . . . Farge, D. (2015). Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP). BONE MARROW TRANSPLANTATION, 50(2), 216-220. doi:10.1038/bmt.2014.248

DOI: 10.1038/bmt.2014.248

PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase (Journal article)

Alonso-Dominguez, J. M., Grinfeld, J., Alikian, M., Marin, D., Reid, A., Daghistani, M., . . . Gerrard, G. (2015). PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase. AMERICAN JOURNAL OF HEMATOLOGY, 90(1), 20-26. doi:10.1002/ajh.23857

DOI: 10.1002/ajh.23857

APL of all risk groups is highly curable with a chemo-free combination of attenuated arsenic trioxide and ATRA (Conference Paper)

Burnett, A. K., Russell, N. H., Hills, R. K., Khwaja, A., Cavenagh, J., Friis, L., . . . Grimwade, D. (2015). APL of all risk groups is highly curable with a chemo-free combination of attenuated arsenic trioxide and ATRA. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 169 (pp. 16). Retrieved from https://www.webofscience.com/

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia (Conference Paper)

Labeit, A. M., Copland, M., Cork, L. M., Hedgley, C. A., Foroni, L., Osborne, W. L., . . . O'Brien, S. G. (2015). Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia. In BLOOD Vol. 126. Retrieved from https://www.webofscience.com/

BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia (Conference Paper)

Ben Batalla, I., Erdmann, R., Jorgensen, H., Mitchell, R., Ernst, T., von Amsberg, G., . . . Loges, S. (2015). BGB324 Inhibits BCR-ABL TKI-Resistant Chronic Myeloid Leukemia. In BLOOD Vol. 126. Retrieved from https://www.webofscience.com/

EFFICACY AND SAFETY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: 6-YEAR FOLLOW-UP OF ENESTND (Conference Paper)

Hughes, T. P., Larson, R. A., Kim, D. W., Issaragrisil, S., le Coutre, P. D., Lobo, C., . . . Kantarjian, H. M. (2015). EFFICACY AND SAFETY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: 6-YEAR FOLLOW-UP OF ENESTND. In HAEMATOLOGICA Vol. 100 (pp. 61). Retrieved from https://www.webofscience.com/

Evidence that the pregnane X and retinoid receptors PXR, RAR and RXR may regulate transcription of the transporter hOCT1 in chronic myeloid leukaemia cells (Journal article)

Austin, G., Holcroft, A., Rinne, N., Wang, L., & Clark, R. E. (2015). Evidence that the pregnane X and retinoid receptors PXR, RAR and RXR may regulate transcription of the transporter hOCT1 in chronic myeloid leukaemia cells. EUROPEAN JOURNAL OF HAEMATOLOGY, 94(1), 74-78. doi:10.1111/ejh.12409

DOI: 10.1111/ejh.12409

PP2A Inhibition By CIP2A or SETBP1 Leads to Elevated Levels of AKT S473 Which Can be Used As a Biomarker of Outcome in Acute Myeloid Leukaemia (Conference Paper)

Hills, R. K., Lucas, C. M., Scott, L. J., Carmell, N., Holcroft, A. K., & Clark, R. E. (2015). PP2A Inhibition By CIP2A or SETBP1 Leads to Elevated Levels of AKT S473 Which Can be Used As a Biomarker of Outcome in Acute Myeloid Leukaemia. In BLOOD Vol. 126. Retrieved from https://www.webofscience.com/

Systematic review to examine the clinical effectiveness and tolerability of systemic anti-cancer therapy for older people with chronic myeloid leukaemia (Report)

Bates, V., Pilkington, G. M., Dickson, R. C., Boland, A., Dundar, Y., & Clark, R. (n.d.). Systematic review to examine the clinical effectiveness and tolerability of systemic anti-cancer therapy for older people with chronic myeloid leukaemia.

Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry (Conference Paper)

Hoffmann, V. S., Baccarani, M., Hasford, J., Lindoerfer, D., Burgstaller, S., Sertic, D., . . . Hehlmann, R. (2015). Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry. In BLOOD Vol. 126. Retrieved from https://www.webofscience.com/

2014

Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd (Conference Paper)

Larson, R. A., Kim, D. -W., Issaragrilsil, S., le Coutre, P., Dorlhiac Llacer, P. E., Etienne, G., . . . Hughes, T. P. (2014). Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd. In BLOOD Vol. 124. doi:10.1182/blood.V124.21.1804.1804

DOI: 10.1182/blood.V124.21.1804.1804

Dual Glutathione-S-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia (Journal article)

Davies, A., Giannoudis, A., Zhang, J. E., Austin, G., Wang, L., Holyoake, T. L., . . . Clark, R. E. (2014). Dual Glutathione-S-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia. CLINICAL PHARMACOLOGY & THERAPEUTICS, 96(6), 694-703. doi:10.1038/clpt.2014.176

DOI: 10.1038/clpt.2014.176

Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia (Journal article)

Lucas, C. M., Harris, R. J., Giannoudis, A., McDonald, E., & Clark, R. E. (2014). Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia. HAEMATOLOGICA, 99(11), 1710-1715. doi:10.3324/haematol.2013.101972

DOI: 10.3324/haematol.2013.101972

Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients (Journal article)

Clark, R. E., Bell, J., Clark, J. O., Braithwaite, B., Vithanarachchi, U., McGinnity, N., . . . Salim, R. (2014). Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients. BLOOD CANCER JOURNAL, 4. doi:10.1038/bcj.2014.79

DOI: 10.1038/bcj.2014.79

ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM). (Conference Paper)

Larson, R. A., Kim, D. -W., Jootar, S., Pasquini, R., Clark, R. E., Lobo, C., . . . Hughes, T. P. (2014). ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 7073). doi:10.1200/jco.2014.32.15_suppl.7073

DOI: 10.1200/jco.2014.32.15_suppl.7073

Tuesday 29th April 2014 Free Communication John Goldman Memorial Symposium (Conference Paper)

O'Brien, S. G., Clark, R. E., Hedgley, C., Apperley, J., Foroni, L., Pocock, C., . . . Goldman, J. M. (2014). Tuesday 29th April 2014 Free Communication John Goldman Memorial Symposium. In BRITISH JOURNAL OF HAEMATOLOGY Vol. 165 (pp. 1). doi:10.1111/bjh.12803

DOI: 10.1111/bjh.12803

A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m2 and 6mg/m2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial (Conference Paper)

Burnett, A. K., Russell, N., Hills, R. K., Cavenagh, J., Kell, J., Jones, G., . . . Clark, R. E. (2014). A Comparison of Single Dose Gemtuzumab Ozogamicin 3mg/m2 and 6mg/m2 Combined with Induction Chemotherapy in Younger Patients with AML: Data from the UK NCRI AML17 Trial. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

A NATIONAL EXPERIENCE OF THE USE OF PONATINIB IN PATIENTS MULTIPLE TYROSINE KINASE INHIBITORS CONFIRMS EFFICACY IN A HEAVILY PRE-TREATED COHORT OF PATIENTS WITH PH plus LEUKAEMIAS (Conference Paper)

Milojkovic, D., Bakir, A., Whitehead, L., Byrne, J., Clark, R. E., Copland, M., . . . Apperley, J. (2014). A NATIONAL EXPERIENCE OF THE USE OF PONATINIB IN PATIENTS MULTIPLE TYROSINE KINASE INHIBITORS CONFIRMS EFFICACY IN A HEAVILY PRE-TREATED COHORT OF PATIENTS WITH PH plus LEUKAEMIAS. In HAEMATOLOGICA Vol. 99 (pp. 335). Retrieved from https://www.webofscience.com/

A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia (Conference Paper)

Dennis, M., Russell, N. H., Panoskaltsis, N., Hemmaway, C. J., Milligan, D., Clark, R. E., . . . Burnett, A. K. (2014). A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

A Randomised Comparison of Daunorubicin 90mg/m2 Vs 60mg/m2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients (Conference Paper)

Burnett, A. K., Russell, N., Hills, R. K., Kell, J., Cavenagh, J., Kjeldsen, L., . . . Clark, R. E. (2014). A Randomised Comparison of Daunorubicin 90mg/m2 Vs 60mg/m2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience (Conference Paper)

Knapper, S., Hills, R. K., Cavenagh, J. D., Kjeldsen, L., Hunter, A. E., Clark, R. E., . . . Burnett, A. K. (2014). A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

Alox5 is down-regulated at diagnosis of chronic myeloid leukaemia (Journal article)

Lucas, C. M., Harris, R. J., Giannoudis, A., McDonald, E., & Clark, R. E. (2014). Alox5 is down-regulated at diagnosis of chronic myeloid leukaemia. Haematologica, epub, September 5th 2014.

BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant (Conference Paper)

Erdmann, R., Jorgensen, H., Ben-Batalla, I., Kruse, N., Micklem, D., von Amsberg, G., . . . Loges, S. (2014). BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials (Journal article)

Baccarani, M., Hoffmann, V. S., Rosti, G., Castagnetti, F., Saussele, S., Guilhot, J., . . . Lindoerfer, D. (2014). Baseline Characteristics of CML Patients Accross Europe - Comparing Real-World Patients with Patient Collectives Included in Clinical Trials. BLOOD, 124(21). Retrieved from https://www.webofscience.com/

CMV∼IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT (Conference Paper)

Peggs, K. S., Tholouli, E., Chakraverty, R., Nikolousis, E., Bloor, A., Devereux, S., . . . Moss, P. (2014). CMV∼IMPACT: Results of a Randomized Controlled Trial of Immuno-Prophylactic Adoptive Cellular Therapy following Sibling Donor Allogeneic HSCT. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

Fertility recovery and pregnancy after autologous hematopoietic stem cell transplantation for autoimmune diseases: a retrospective study of the EBMT Autoimmune Diseases Working Party (Journal article)

Snarski, E., Snowden, J. A., Oliveira, M. C., Simoes, B., Badoglio, M., Carlson, K., . . . Farge, D. (2014). Fertility recovery and pregnancy after autologous hematopoietic stem cell transplantation for autoimmune diseases: a retrospective study of the EBMT Autoimmune Diseases Working Party. Blood & Marrow Transplantation, in pre, accepted 18 Sept 2014.

Ikaros transcripts Ik6/10 and levels of full-length transcript are critical for chronic myeloid leukaemia blast crisis transformation (Journal article)

Wang, L. H., Howarth, A., & Clark, R. E. (2014). Ikaros transcripts Ik6/10 and levels of full-length transcript are critical for chronic myeloid leukaemia blast crisis transformation. Leukemia, 28, 1745-1747. doi:10.1038/leu.2014.99

DOI: 10.1038/leu.2014.99

Leukemia Stem Cell Potential of Different Progenitor Subpopulations in Myeloid Blast Phase CML (Conference Paper)

Kinstrie, R., Karamitros, D., Goardon, N., Morrison, H., Clark, R. E., Vyas, P., & Copland, M. (2014). Leukemia Stem Cell Potential of Different Progenitor Subpopulations in Myeloid Blast Phase CML. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

PLERIXAFOR IS COST-EFFECTIVE FOR FIRST LINE STEM CELL MOBILISATION: INDIVIDUAL PATIENT COSTING ANALYSIS OF THE LIVERPOOL PHANTASTIC TRIAL (Conference Paper)

Haycox, A., Richards, S., & Clark, R. E. (2014). PLERIXAFOR IS COST-EFFECTIVE FOR FIRST LINE STEM CELL MOBILISATION: INDIVIDUAL PATIENT COSTING ANALYSIS OF THE LIVERPOOL PHANTASTIC TRIAL. In HAEMATOLOGICA Vol. 99 (pp. 490-491). Retrieved from https://www.webofscience.com/

Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML (Conference Paper)

O'Brien, S. G., Hedgley, C., Adams, S., Foroni, L., Apperley, J. F., Holyoake, T. L., . . . Clark, R. E. (2014). Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML. In BLOOD Vol. 124. Retrieved from https://www.webofscience.com/

THE EUTOS POPULATION BASED REGISTRY - INCIDENCES OF CML ACROSS EUROPE (Conference Paper)

Hoffmann, V., Lindoerfer, D., Thaler, J., Labar, B., Melanthiou, F., Mayer, J., . . . Baccarani, M. (2014). THE EUTOS POPULATION BASED REGISTRY - INCIDENCES OF CML ACROSS EUROPE. In HAEMATOLOGICA Vol. 99 (pp. 72). Retrieved from https://www.webofscience.com/

THE EUTOS POPULATION-BASED REGISTRY: EVALUATION OF BASELINE CHARACTERISTICS AND FIRST TREATMENT CHOICES OF 2983 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS FROM 20 EUROPEAN COUNTRIES (Conference Paper)

Lindoerfer, D., Hoffmann, V. S., Rosti, G., Castagnetti, F., Saussele, S., Guilhot, J., . . . Baccarani, M. (2014). THE EUTOS POPULATION-BASED REGISTRY: EVALUATION OF BASELINE CHARACTERISTICS AND FIRST TREATMENT CHOICES OF 2983 NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS FROM 20 EUROPEAN COUNTRIES. In HAEMATOLOGICA Vol. 99 (pp. 238-239). Retrieved from https://www.webofscience.com/

TRANSCRIPT LEVELS OF THE HEDGEHOG PATHWAY MEMBERS PTCH1 AND SMO ARE PREDICTIVE OF IMATINIB FAILURE IN PRE-TREATMENT CHRONIC MYELOID LEUKAEMIA (Conference Paper)

Gerrard, G., Hagkarim, N. C., Szydlo, R., Alikian, M., Alonso-Dominguez, J. M., Grinfeld, J., . . . Foroni, L. (2014). TRANSCRIPT LEVELS OF THE HEDGEHOG PATHWAY MEMBERS PTCH1 AND SMO ARE PREDICTIVE OF IMATINIB FAILURE IN PRE-TREATMENT CHRONIC MYELOID LEUKAEMIA. In HAEMATOLOGICA Vol. 99 (pp. 510). Retrieved from https://www.webofscience.com/

The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia (Journal article)

Giannoudis, A., Davies, A., Harris, B., Lucas, C., Pirmohamed, M., & Clark, R. (2014). The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia. Leukemia, 28(6), 1360-1363. doi:10.1038/leu.2014.38

DOI: 10.1038/leu.2014.38

2013

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia (Journal article)

Grinfeld, J., Gerrard, G., Alikian, M., Alonso-Dominguez, J., Ale, S., Valganon, M., . . . Foroni, L. (2013). A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 163(5), 631-639. doi:10.1111/bjh.12591

DOI: 10.1111/bjh.12591

Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. (Journal article)

Gallipoli, P., Stobo, J., Heaney, N., Nicolini, F. E., Clark, R., Wilson, G., . . . Holyoake, T. L. (2013). Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.. British journal of haematology, 163(5), 674-676. doi:10.1111/bjh.12532

DOI: 10.1111/bjh.12532

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. (Journal article)

Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., . . . Hehlmann, R. (2013). European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.. Blood, 122(6), 872-884. doi:10.1182/blood-2013-05-501569

DOI: 10.1182/blood-2013-05-501569

A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia. (Journal article)

Francis, S., Lucas, C., Lane, S., Wang, L., Watmough, S., Knight, K., . . . Clark, R. E. (2013). A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.. Leukemia research, 37(7), 752-758. doi:10.1016/j.leukres.2013.04.003

DOI: 10.1016/j.leukres.2013.04.003

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. (Journal article)

Experts in Chronic Myeloid Leukemia. (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.. Blood, 121(22), 4439-4442. doi:10.1182/blood-2013-03-490003

DOI: 10.1182/blood-2013-03-490003

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies (Journal article)

Neelakantan, P., Gerrard, G., Lucas, C., Milojkovic, D., May, P., Wang, L., . . . Marin, D. (2013). Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. BLOOD, 121(14), 2739-2742. doi:10.1182/blood-2012-11-466037

DOI: 10.1182/blood-2012-11-466037

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia (Journal article)

Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. BLOOD, 121(4), 628-637. doi:10.1182/blood-2012-01-405035

DOI: 10.1182/blood-2012-01-405035

Can the combined assessment of BCR-ABL1 transcript levels at 3 and 6 months improve the prognostic value of the 3 month measurement for CML patients who start treatment with tyrosine kinase inhibitors? Implications for early intervention strategies (Journal article)

Neelakantan, P., Gerrard, G., Lucas, C. M., Hedgley, C., Milojkovic, D., May, P., . . . Marin, D. (2013). Can the combined assessment of BCR-ABL1 transcript levels at 3 and 6 months improve the prognostic value of the 3 month measurement for CML patients who start treatment with tyrosine kinase inhibitors? Implications for early intervention strategies. Blood, 121, 2739-2742.

Pulsed imatinib with or without G-CSF is a safe treatment approach and potentially improves molecular responses in CML patients in complete cytogenetic response compared to continuous imatinib: results from 5 years follow-up of a pilot study (GIMI) (Journal article)

Gallipoli, P., Stobo, J., Heaney, N., Kaeda, J., Nicolini, F. E., Clark, R. E., . . . Holyoake, T. L. (2013). Pulsed imatinib with or without G-CSF is a safe treatment approach and potentially improves molecular responses in CML patients in complete cytogenetic response compared to continuous imatinib: results from 5 years follow-up of a pilot study (GIMI). British Journal of Haematology, 163, 674-676.

Response to the letter to the Editor. Tzvetkov et al, "The hOCT1 SNPs Met420del and Met408Val alter imatinib uptake: Does the apparently predictive haplotype Met408-Del420 really exist"? (Journal article)

Giannoudis, A., Pirmohamed, M., & Clark, R. E. (2013). Response to the letter to the Editor. Tzvetkov et al, "The hOCT1 SNPs Met420del and Met408Val alter imatinib uptake: Does the apparently predictive haplotype Met408-Del420 really exist"?. Blood e-letters. Retrieved from http://bloodjournal.hematologylibrary.org/

The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia (Journal article)

Giannoudis, A., Wang, L., Jorgensen, A. L., Xinarianos, G., Davies, A., Pushpakom, S., . . . Clark, R. E. (2013). The hOCT1 single nucleotide polymorphisms M420del and M408V alter imatinib uptake and modify clinical outcome in imatinib treated chronic myeloid leukaemia. Blood, 121, 628-637.

2012

Erratum: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up (Journal article)

Larson, R. A., Hochhaus, A., Hughes, T. P., Clark, R. E., Etienne, G., Kim, D. -W., . . . Kantarjian, H. M. (2012). Erratum: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia, 26(10), 2302. doi:10.1038/leu.2012.175

DOI: 10.1038/leu.2012.175

Serine 162, an Essential Residue for the Mitochondrial Localization, Stability and Anti-Apoptotic Function of Mcl-1 (Journal article)

Thomas, L. W., Lam, C., Clark, R. E., White, M. R. H., Spiller, D. G., Moots, R. J., & Edwards, S. W. (2012). Serine 162, an Essential Residue for the Mitochondrial Localization, Stability and Anti-Apoptotic Function of Mcl-1. PLOS ONE, 7(9). doi:10.1371/journal.pone.0045088

DOI: 10.1371/journal.pone.0045088

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia. (Journal article)

Ali, S., Sergeant, R., O'Brien, S. G., Foroni, L., Hedgley, C., Gerrard, G., . . . Rezvani, K. (2012). Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.. Blood, 120(3), 697-698. doi:10.1182/blood-2012-04-421016

DOI: 10.1182/blood-2012-04-421016

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib (Journal article)

Marin, D., Hedgley, C., Clark, R. E., Apperley, J., Foroni, L., Milojkovic, D., . . . O'Brien, S. (2012). Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. BLOOD, 120(2), 291-294. doi:10.1182/blood-2012-01-407486

DOI: 10.1182/blood-2012-01-407486

Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. (Journal article)

Guilhot, J., Baccarani, M., Clark, R. E., Cervantes, F., Guilhot, F., Hochhaus, A., . . . Hehlmann, R. (2012). Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.. Blood, 119(25), 5963-5971. doi:10.1182/blood-2011-10-383711

DOI: 10.1182/blood-2011-10-383711

Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009. (Journal article)

Snowden, J. A., Pearce, R. M., Lee, J., Kirkland, K., Gilleece, M., Veys, P., . . . BSBMT Clinical Trials Committee. (2012). Haematopoietic stem cell transplantation (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009.. British journal of haematology, 157(6), 742-746. doi:10.1111/j.1365-2141.2012.09122.x

DOI: 10.1111/j.1365-2141.2012.09122.x

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. (Journal article)

Larson, R. A., Yin, O. Q. P., Hochhaus, A., Saglio, G., Clark, R. E., Nakamae, H., . . . le Coutre, P. D. (2012). Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.. European journal of clinical pharmacology, 68(5), 723-733. doi:10.1007/s00228-011-1200-7

DOI: 10.1007/s00228-011-1200-7

Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis (Journal article)

Forchap, S. L., Pirmohamed, M., & Clark, R. E. (2012). Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis. LEUKEMIA, 26(3), 490-498. doi:10.1038/leu.2011.231

DOI: 10.1038/leu.2011.231

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. (Journal article)

Marin, D., Ibrahim, A. R., Lucas, C., Gerrard, G., Wang, L., Szydlo, R. M., . . . Foroni, L. (2012). Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30(3), 232-238. doi:10.1200/jco.2011.38.6565

DOI: 10.1200/jco.2011.38.6565

Haemopoietic stem cell transplantation in severe autoimmune diseases: Analysis of UK outcomes from the BSBMT database 1997-2009 (Journal article)

Snowden, J. A., Pearce, R. M., Lee, J., Kirkland, K., Gilleece, M., Veys, P., . . . Cook, G. (2012). Haemopoietic stem cell transplantation in severe autoimmune diseases: Analysis of UK outcomes from the BSBMT database 1997-2009. British Journal of Haematology, 157, 742-746.

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib (Journal article)

Marin, D., Gabriel, I. H., Ahmad, S., Foroni, L., de Lavallade, H., Clark, R., . . . Rezvani, K. (2012). KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. LEUKEMIA, 26(2), 296-302. doi:10.1038/leu.2011.180

DOI: 10.1038/leu.2011.180

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. (Journal article)

Larson, R. A., Hochhaus, A., Hughes, T. P., Clark, R. E., Etienne, G., Kim, D. -W., . . . Kantarjian, H. M. (2012). Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.. Leukemia, 26(10), 2197-2203. doi:10.1038/leu.2012.134

DOI: 10.1038/leu.2012.134

Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells (Journal article)

Wang, L., Giannoudis, A., Austin, G., & Clark, R. E. (2012). Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells. EXPERIMENTAL HEMATOLOGY, 40(10), 811-819. doi:10.1016/j.exphem.2012.05.013

DOI: 10.1016/j.exphem.2012.05.013

Peroxisome proliferator-activated receptors (PPAR) upregulate the imatinib transporter hOCT1 in chronic myeloid leukaemia (Journal article)

Wang, L., Giannoudis, A., Austin, G., & Clark, R. E. (2012). Peroxisome proliferator-activated receptors (PPAR) upregulate the imatinib transporter hOCT1 in chronic myeloid leukaemia. Experimental Hematology, 40, 811-819.

The predictive value of early molecular response in patients with chronic myeloid leukaemia in chronic phase treated with dasatinib as first line therapy. (Journal article)

Marin, D., Hedgley, C., Clark, R. E., Apperley, J. F., Foroni, L., Milojkovic, D., . . . O'Brien, S. (2012). The predictive value of early molecular response in patients with chronic myeloid leukaemia in chronic phase treated with dasatinib as first line therapy.. Blood, 120, 291-294.

2011

Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed. (Journal article)

Ibrahim, A. R., Clark, R. E., Holyoake, T. L., Byrne, J., Shepherd, P., Apperley, J. F., . . . Marin, D. (2011). Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed.. Haematologica, 96(12), 1779-1782. doi:10.3324/haematol.2011.049759

DOI: 10.3324/haematol.2011.049759

Rapid diagnosis of chronic myeloid leukemia by flow cytometric detection of BCR-ABL1 protein (Journal article)

Lucas, C. M., Fagan, J. L., Carter, A., Swale, B., Evans, C., Clark, R. E., & Harris, R. J. (2011). Rapid diagnosis of chronic myeloid leukemia by flow cytometric detection of BCR-ABL1 protein. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 96(7), 1077-1078. doi:10.3324/haematol.2011.043166

DOI: 10.3324/haematol.2011.043166

Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression (Journal article)

Lucas, C. M., Harris, R. J., Giannoudis, A., Copland, M., Slupsky, J. R., & Clark, R. E. (2011). Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. BLOOD, 117(24), 6660-6668. doi:10.1182/blood-2010-08-304477

DOI: 10.1182/blood-2010-08-304477

Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. (Journal article)

Schmidt, T., Kharabi Masouleh, B., Loges, S., Cauwenberghs, S., Fraisl, P., Maes, C., . . . Carmeliet, P. (2011). Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.. Cancer cell, 19(6), 740-753. doi:10.1016/j.ccr.2011.05.007

DOI: 10.1016/j.ccr.2011.05.007

BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients. (Journal article)

Rojas, J. M., Knight, K., Watmough, S., Bell, J., Wang, L., Callaghan, T., & Clark, R. E. (2011). BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients.. Leukemia research, 35(3), 369-372. doi:10.1016/j.leukres.2010.05.028

DOI: 10.1016/j.leukres.2010.05.028

A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib. (Journal article)

Estabragh, Z. R., Knight, K., Watmough, S. J., Lane, S., Vinjamuri, S., Hart, G., & Clark, R. E. (2011). A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib.. Leukemia research, 35(1), 49-51. doi:10.1016/j.leukres.2010.08.020

DOI: 10.1016/j.leukres.2010.08.020

2010

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors. (Journal article)

Daghistani, M., Marin, D., Khorashad, J. S., Wang, L., May, P. C., Paliompeis, C., . . . Reid, A. G. (2010). EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.. Blood, 116(26), 6014-6017. doi:10.1182/blood-2010-01-264234

DOI: 10.1182/blood-2010-01-264234

Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive. (Journal article)

Rojas, J. M., Wang, L., Owen, S., Knight, K., Watmough, S. J., & Clark, R. E. (2010). Naturally occurring CD4+ CD25+ FOXP3+ T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive.. Experimental hematology, 38(12), 1209-1218. doi:10.1016/j.exphem.2010.09.004

DOI: 10.1016/j.exphem.2010.09.004

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study. (Journal article)

Giles, F. J., Rosti, G., Beris, P., Clark, R. E., le Coutre, P., Mahon, F. -X., . . . Saglio, G. (2010). Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.. Expert review of hematology, 3(6), 665-673. doi:10.1586/ehm.10.61

DOI: 10.1586/ehm.10.61

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. (Journal article)

Chakraverty, R., Orti, G., Roughton, M., Shen, J., Fielding, A., Kottaridis, P., . . . Mackinnon, S. (2010). Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.. Blood, 116(16), 3080-3088. doi:10.1182/blood-2010-05-286856

DOI: 10.1182/blood-2010-05-286856

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. (Journal article)

Saglio, G., Kim, D. -W., Issaragrisil, S., le Coutre, P., Etienne, G., Lobo, C., . . . ENESTnd Investigators. (2010). Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.. The New England journal of medicine, 362(24), 2251-2259. doi:10.1056/nejmoa0912614

DOI: 10.1056/nejmoa0912614

High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression. (Journal article)

Boultwood, J., Perry, J., Zaman, R., Fernandez-Santamaria, C., Littlewood, T., Kusec, R., . . . Wainscoat, J. S. (2010). High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression.. Leukemia, 24(6), 1139-1145. doi:10.1038/leu.2010.65

DOI: 10.1038/leu.2010.65

Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography (Journal article)

Davies, A., Hayes, A. K., Knight, K., Watmough, S. J., Pirmohamed, M., & Clark, R. E. (2010). Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography. LEUKEMIA RESEARCH, 34(6), 702-707. doi:10.1016/j.leukres.2009.11.009

DOI: 10.1016/j.leukres.2009.11.009

European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. (Journal article)

Burnett, A. K., Russell, N. H., Kell, J., Dennis, M., Milligan, D., Paolini, S., . . . Hills, R. K. (2010). European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(14), 2389-2395. doi:10.1200/jco.2009.26.4242

DOI: 10.1200/jco.2009.26.4242

BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia (Journal article)

Lucas, C. M., Harris, R. J., Giannoudis, A., Knight, K., Watmough, S. J., & Clark, R. E. (2010). BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 149(3), 458-460. doi:10.1111/j.1365-2141.2009.08066.x

DOI: 10.1111/j.1365-2141.2009.08066.x

A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers. (Journal article)

Dunwell, T., Hesson, L., Rauch, T. A., Wang, L., Clark, R. E., Dallol, A., . . . Latif, F. (2010). A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers.. Molecular cancer, 9, 44. doi:10.1186/1476-4598-9-44

DOI: 10.1186/1476-4598-9-44

A Genome-wide screen identifies novel frequently methylated genes in leukemia and genes associated with clinical outcome in chronic myeloid leukaemia (Journal article)

Dunwell, T., Hesson, L., Rauch, T., Wang, L., Clark, R. E., Dallol, A., . . . Latif, F. (2010). A Genome-wide screen identifies novel frequently methylated genes in leukemia and genes associated with clinical outcome in chronic myeloid leukaemia. Molecular Cancer, 9, 44-55.

Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype (Journal article)

Grant, H., Jiang, X., Stebbing, J., Foroni, L., Craddock, C., Griffiths, M., . . . Woolfson, A. (2010). Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype. LEUKEMIA, 24(10), 1817-1821. doi:10.1038/leu.2010.179

DOI: 10.1038/leu.2010.179

Diverging effects of HLA–DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles (Journal article)

Shaw, B. E., Mayor, N. P., Russell, N. H., Apperley, J. F., Clark, R. E., Cornish, J., . . . Madrigal, J. A. (2010). Diverging effects of HLA–DPB1 matching status on outcome following unrelated donor transplantation depending on disease stage and the degree of matching for other HLA alleles. Leukemia, 24(1), 58-65. doi:10.1038/leu.2009.239

DOI: 10.1038/leu.2009.239

EVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib (Journal article)

Daghistani, M., Marin, D., Khorashad, J. S., May, P. C., Paliompeis, C., Milojkovic, D., . . . Reid, A. G. (2010). EVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib. Blood, 116, 6014-6017.

Naturally occurring CD4+ CD25+ FOXP3+ T regulatory cells are increased in chronic myeloid leukaemia patients with high BCR-ABL transcripts and can suppress anti-BCR-ABL responses (Journal article)

Rojas, J. M., Wang, L. H., Owen, S., Knight, K., Watmough, S., & Clark, R. E. (2010). Naturally occurring CD4+ CD25+ FOXP3+ T regulatory cells are increased in chronic myeloid leukaemia patients with high BCR-ABL transcripts and can suppress anti-BCR-ABL responses. Experimental Hematology, 38, 1209-1218.

Nilotinib is superior to imatinib as first line therapy of chronic myeloid leukemia (CML): the ENESTnd study as a landmark on the path to cure in CML (Journal article)

Giles, F. J., Rosti, G., Beris, P., Clark, R. E., le Coutre, P., Mahon, F. -X., . . . Saglio, G. (2010). Nilotinib is superior to imatinib as first line therapy of chronic myeloid leukemia (CML): the ENESTnd study as a landmark on the path to cure in CML. Expert Reviews in Haematology, 3, 665-673.

THE PRE-TREATMENT LEVELS OF PROTEIN PHOSPHATASE 2A (PP2A) AND ITS INHIBITOR SET CAN PREDICT PATIENTS DESTINED TO PROGRESS TO BLAST CRISIS OF CML (Journal article)

Lucas, C., Harris, R. J., Giannoudis, A., & Clark, R. (2010). THE PRE-TREATMENT LEVELS OF PROTEIN PHOSPHATASE 2A (PP2A) AND ITS INHIBITOR SET CAN PREDICT PATIENTS DESTINED TO PROGRESS TO BLAST CRISIS OF CML. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 95, 338. Retrieved from https://www.webofscience.com/

The pCrKL/CrKL ratio at initial diagnosis is predictive of treatment outcome in chronic myeloid leukaemia (Journal article)

Lucas, C. M., Harris, R. J., Giannoudis, A., Knight, K., Watmough, S. J., & Clark, R. E. (2010). The pCrKL/CrKL ratio at initial diagnosis is predictive of treatment outcome in chronic myeloid leukaemia. British Journal of Haematology, 149, 158-160.

2009

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript (Journal article)

Lucas, C. M., Harris, R. J., Giannoudis, A., Davies, A., Knight, K., Watmough, S. J., . . . Clark, R. E. (2009). Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 94(10), 1362-1367. doi:10.3324/haematol.2009.009134

DOI: 10.3324/haematol.2009.009134

Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. (Journal article)

Patel, B., Kirkland, K. E., Szydlo, R., Pearce, R. M., Clark, R. E., Craddock, C., . . . Marks, D. I. (2009). Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission.. Haematologica, 94(10), 1399-1406. doi:10.3324/haematol.2009.008649

DOI: 10.3324/haematol.2009.008649

Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia. (Journal article)

Clark, R. E. (2009). Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia.. Leukemia research, 33(9), 1151-1155. doi:10.1016/j.leukres.2009.04.001

DOI: 10.1016/j.leukres.2009.04.001

Soluble HLA/peptide monomers cross-linked with co-stimulatory antibodies onto a streptavidin core molecule efficiently stimulate antigen-specific T cell responses. (Journal article)

Rusakiewicz, S., Aubert, G., Clark, R. E., Madrigal, A. J., Dodi, A. I., & Travers, P. J. (2009). Soluble HLA/peptide monomers cross-linked with co-stimulatory antibodies onto a streptavidin core molecule efficiently stimulate antigen-specific T cell responses.. Cancer immunology, immunotherapy : CII, 58(9), 1459-1470. doi:10.1007/s00262-009-0711-x

DOI: 10.1007/s00262-009-0711-x

Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable? (Journal article)

Riley, C. L., Mathieu, M. G., Clark, R. E., McArdle, S. E. B., & Rees, R. C. (2009). Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?. Cancer immunology, immunotherapy : CII, 58(9), 1489-1499. doi:10.1007/s00262-009-0675-x

DOI: 10.1007/s00262-009-0675-x

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. (Journal article)

Grimwade, D., Jovanovic, J. V., Hills, R. K., Nugent, E. A., Patel, Y., Flora, R., . . . Burnett, A. K. (2009). Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27(22), 3650-3658. doi:10.1200/jco.2008.20.1533

DOI: 10.1200/jco.2008.20.1533

T cell function in chronic myeloid leukemia and its treatment with tyrosine kinase inhibitors--clues from and for sarcoidosis. (Journal article)

Punekar, M., Thachil, J., Salim, R., Watmough, S., & Clark, R. E. (2009). T cell function in chronic myeloid leukemia and its treatment with tyrosine kinase inhibitors--clues from and for sarcoidosis.. Leukemia research, 33(7), e91-e92. doi:10.1016/j.leukres.2008.11.032

DOI: 10.1016/j.leukres.2008.11.032

A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. (Journal article)

Drummond, M. W., Heaney, N., Kaeda, J., Nicolini, F. E., Clark, R. E., Wilson, G., . . . Holyoake, T. L. (2009). A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response.. Leukemia, 23(6), 1199-1201. doi:10.1038/leu.2009.43

DOI: 10.1038/leu.2009.43

Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters (Journal article)

Davies, A., Jordanides, N. E., Giannoudis, A., Lucas, C. M., Hatziieremia, S., Harris, R. J., . . . Mountford, J. C. (2009). Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. LEUKEMIA, 23(11), 1999-2006. doi:10.1038/leu.2009.166

DOI: 10.1038/leu.2009.166

2008

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia (Journal article)

Giannoudis, A., Davies, A., Lucas, C. M., Harris, R. J., Pirmohamed, M., & Clark, R. E. (2008). Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. BLOOD, 112(8), 3348-3354. doi:10.1182/blood-2007-10-116236

DOI: 10.1182/blood-2007-10-116236

The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation. (Journal article)

Stelljes, M., van Biezen, A., Slavin, S., Olavarria, E., Clark, R. E., Nagler, A., . . . complications subcommittee of the Chronic Leukemia Working Party. (2008). The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation.. Bone marrow transplantation, 42(11), 739-742. doi:10.1038/bmt.2008.254

DOI: 10.1038/bmt.2008.254

Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia (Journal article)

Clark, R. E., Davies, A., Pirmohamed, M., & Giannoudis, A. (2008). Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. LEUKEMIA & LYMPHOMA, 49(4), 639-642. doi:10.1080/10428190701858823

DOI: 10.1080/10428190701858823

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia (Journal article)

Wang, L., Giannoudis, A., Lane, S., Williamson, P., Pirmohamed, M., & Clark, R. E. (2008). Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. CLINICAL PHARMACOLOGY & THERAPEUTICS, 83(2), 258-264. doi:10.1038/sj.clpt.6100268

DOI: 10.1038/sj.clpt.6100268

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials (Journal article)

Lucas, C. M., Wang, L., Austin, G. M., Knight, K., Watmough, S. J., Shwe, K. H., . . . Clark, R. E. (2008). A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. LEUKEMIA, 22(10), 1963-1966. doi:10.1038/leu.2008.225

DOI: 10.1038/leu.2008.225

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia (Journal article)

Wang, L., Giannoudis, A., Lane, S., Williamson, P., Pirmohamed, M., & Clark, R. E. (2008). Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clinical Pharmacology and Therapeutics, 83(2), 258-264. doi:10.1038/sj.clpt.6100268

DOI: 10.1038/sj.clpt.6100268

Immunotherapy in chronic myeloid leukemia (Chapter)

Clark, R. E. (2008). Immunotherapy in chronic myeloid leukemia. In Chronic Myeloproliferative Disorders (pp. 118-125).

2007

Evidence that a BCR-ABL fusion peptide does not induce lymphocyte proliferation or cytokine production in vitro. (Journal article)

Abu-Eisha, H. M., Butt, N. M., Clark, R. E., Christmas, S. E., & Christmas, S. E. (2007). Evidence that a BCR-ABL fusion peptide does not induce lymphocyte proliferation or cytokine production in vitro.. Leukemia research, 31(12), 1675-1681. doi:10.1016/j.leukres.2007.01.007

DOI: 10.1016/j.leukres.2007.01.007

Immunotherapeutic strategies in chronic myeloid leukemia. (Journal article)

Clark, R. E. (2007). Immunotherapeutic strategies in chronic myeloid leukemia.. Current hematologic malignancy reports, 2(2), 89-94. doi:10.1007/s11899-007-0013-3

DOI: 10.1007/s11899-007-0013-3

Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. (Journal article)

Rojas, J. M., Knight, K., Wang, L., & Clark, R. E. (2007). Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.. Leukemia, 21(11), 2287-2295. doi:10.1038/sj.leu.2404858

DOI: 10.1038/sj.leu.2404858

Dasatinib: a new therapy for myeloproliferative disorders (Journal article)

Clark, R. E. (2007). Dasatinib: a new therapy for myeloproliferative disorders. Myeloproliferative Disorders in Practice, 1, 3-5.

Definition of the breakpoint fusion peptides for HLA-B8 as well as HLA-A3 in CML cells. (Chapter)

Dodi, I. A., Rusakiewicz, S., Aubert, G., Clark, R. E., Creaser, C., Bonner, P., . . . Madrigal, J. A. (2007). Definition of the breakpoint fusion peptides for HLA-B8 as well as HLA-A3 in CML cells.. In J. A. Hansen (Ed.), Immunobiology of the Human MHC; proceedings of 13th International workshop and congress. Vol II. (pp. 275-280). Seattle: International Histocompatibily Workshop Group press.

Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. (Journal article)

Ruutu, T., Barosi, G., Benjamin, R. J., Clark, R. E., George, J. N., Gratwohl, A., . . . European LeukemiaNet. (2007). Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group.. Haematologica, 92(1), 95-100. doi:10.3324/haematol.10699

DOI: 10.3324/haematol.10699

2006

Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. (Journal article)

Saccardi, R., Kozak, T., Bocelli-Tyndall, C., Fassas, A., Kazis, A., Havrdova, E., . . . Autoimmune Diseases Working Party of EBMT. (2006). Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database.. Multiple sclerosis (Houndmills, Basingstoke, England), 12(6), 814-823. doi:10.1177/1352458506071301

DOI: 10.1177/1352458506071301

Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter. (Journal article)

Clark, R., Kerr, I. D., & Callaghan, R. (2006). Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter.. British journal of pharmacology, 149(5), 506-515. doi:10.1038/sj.bjp.0706904

DOI: 10.1038/sj.bjp.0706904

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. (Journal article)

Knapper, S., Burnett, A. K., Littlewood, T., Kell, W. J., Agrawal, S., Chopra, R., . . . Small, D. (2006). A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy.. Blood, 108(10), 3262-3270. doi:10.1182/blood-2006-04-015560

DOI: 10.1182/blood-2006-04-015560

The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy. (Journal article)

Cook, G., Clark, R. E., Crawley, C., Mackinnon, S., Russell, N., Thomson, K., . . . Marks, D. I. (2006). The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 12(3), 293-300. doi:10.1016/j.bbmt.2005.10.019

DOI: 10.1016/j.bbmt.2005.10.019

The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia (Journal article)

Wang, L. H., Knight, K., Lucas, C., & Clark, R. E. (2006). The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 91(2), 235-239. Retrieved from https://www.webofscience.com/

2005

Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT). (Journal article)

Cummins, M., Cwynarski, K., Marktel, S., Dazzi, F., Cavenagh, J., Clark, R. E., . . . Clinical Trials Committee British Society of Blood & Marrow Transplantation (BSBMT). (2005). Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT).. Bone marrow transplantation, 36(12), 1065-1069. doi:10.1038/sj.bmt.1705180

DOI: 10.1038/sj.bmt.1705180

Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. (Journal article)

Butt, N. M., Rojas, J. M., Wang, L., Christmas, S. E., Abu-Eisha, H. M., & Clark, R. E. (2005). Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.. Haematologica, 90(10), 1315-1323.

hOCT 1 and resistance to imatinib (Journal article)

Crossman, L. C., Druker, B. J., & Deininger, M. W. N. (2005). hOCT 1 and resistance to imatinib. BLOOD, 106(3), 1133-1134. doi:10.1182/blood-2005-02-0694

DOI: 10.1182/blood-2005-02-0694

Ancestim associated with Filgrastim and/or chemotherapy can improve blood progenitor yields in patients who previously failed mobilisation. (Journal article)

Mijovic, A., Russell, N., Clark, R. E., Morris, T. C. M., Browne, P., Crown, J., . . . Mufti, G. J. (2005). Ancestim associated with Filgrastim and/or chemotherapy can improve blood progenitor yields in patients who previously failed mobilisation.. Bone marrow transplantation, 35(10), 1019. doi:10.1038/sj.bmt.1704950

DOI: 10.1038/sj.bmt.1704950

Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients (Journal article)

Butt, N. M., Rojas, J. M., Wang, L., Christmas, S. E., Abu-Eisha, H. M., & Clark, R. E. (2005). Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients. Haematologica, 90(10), 1315-1323. Retrieved from http://www.haematologica.org/journal/2005/901315.pdf

The immune response to chronic myeloid leukaemia (Chapter)

Clark, R. E. (2005). The immune response to chronic myeloid leukaemia. In R. F. Romero (Ed.), Focus on Leukemia Research (pp. 27-60). New York: Nova Science Publishers, Inc.

Uncertainties in the use of imatinib in chronic myeloid leukaemia (Journal article)

Clark, R. E., & Wang, L. (2005). Uncertainties in the use of imatinib in chronic myeloid leukaemia. British Journal of Cancer Management, 1, 11-14.

2004

Active transport of imatinib into and out of cells: implications for drug resistance (Journal article)

Thomas, J., Wang, L. H., Clark, R. E., & Pirmohamed, M. (2004). Active transport of imatinib into and out of cells: implications for drug resistance. BLOOD, 104(12), 3739-3745. doi:10.1182/blood-2003-12-4276

DOI: 10.1182/blood-2003-12-4276

A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. (Journal article)

Cook, G., Clark, R. E., Morris, T. C. M., Robertson, M., Lucie, N. P., Anderson, S., . . . Franklin, I. M. (2004). A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.. British journal of haematology, 126(6), 792-798. doi:10.1111/j.1365-2141.2004.05127.x

DOI: 10.1111/j.1365-2141.2004.05127.x

Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib. (Journal article)

Heartin, E., Walkinshaw, S., & Clark, R. E. (2004). Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib.. Leukemia & lymphoma, 45(6), 1307-1308. doi:10.1080/10428190310001645195

DOI: 10.1080/10428190310001645195

Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib. (Journal article)

Wang, L., Butt, N. M., Atherton, M. G., & Clark, R. E. (2004). Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib.. Leukemia, 18(5), 1025-1027. doi:10.1038/sj.leu.2403342

DOI: 10.1038/sj.leu.2403342

BCR-ABL-specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation. (Journal article)

Butt, N. M., Wang, L., Abu-Eisha, H. M., Christmas, S. E., & Clark, R. E. (2004). BCR-ABL-specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation.. Blood, 103(8), 3245. doi:10.1182/blood-2003-11-4086

DOI: 10.1182/blood-2003-11-4086

Active transport of imatinib into and out of cells: implications for drug resistance (Journal article)

Thomas, J., Wang, L., Clark, R. E., & Pirmohamed, M. (2004). Active transport of imatinib into and out of cells: implications for drug resistance. Blood, 104(12), 3739-3745. doi:10.1182/blood-2003-12-4276

DOI: 10.1182/blood-2003-12-4276

2003

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. (Journal article)

Kell, W. J., Burnett, A. K., Chopra, R., Yin, J. A. L., Clark, R. E., Rohatiner, A., . . . Milligan, D. W. (2003). A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.. Blood, 102(13), 4277-4283. doi:10.1182/blood-2003-05-1620

DOI: 10.1182/blood-2003-05-1620

Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia. (Journal article)

Butt, N. M., & Clark, R. E. (2003). Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia.. Bone marrow transplantation, 32(9), 909-913. doi:10.1038/sj.bmt.1704244

DOI: 10.1038/sj.bmt.1704244

Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. (Journal article)

Drummond, M. W., Marin, D., Clark, R. E., Byrne, J. L., Holyoake, T. L., Lennard, A., & United Kingdom Chronic Myeloid Leukaemia (UK CML) Working Party. (2003). Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission.. British journal of haematology, 123(3), 479-483. doi:10.1046/j.1365-2141.2003.04599.x

DOI: 10.1046/j.1365-2141.2003.04599.x

Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. (Journal article)

Gorin, N. C., Labopin, M., Rocha, V., Arcese, W., Beksac, M., Gluckman, E., . . . European Cooperative Group for Blood and Marrow Transplantation Acute Leukemia Working Party. (2003). Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow.. Blood, 102(8), 3043-3051. doi:10.1182/blood-2003-03-0665

DOI: 10.1182/blood-2003-03-0665

BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis. (Journal article)

Schultheis, B., Wang, L., Clark, R. E., & Melo, J. V. (2003). BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis.. Leukemia, 17(10), 2054-2055. doi:10.1038/sj.leu.2403079

DOI: 10.1038/sj.leu.2403079

Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions. (Journal article)

Huntly, B. J. P., Guilhot, F., Reid, A. G., Vassiliou, G., Hennig, E., Franke, C., . . . Deininger, M. W. N. (2003). Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.. Blood, 102(6), 2205-2212. doi:10.1182/blood-2002-09-2763

DOI: 10.1182/blood-2002-09-2763

CD34 positive selection as prophylaxis against graft versus host disease in allogeneic peripheral blood stem cell transplantation. (Journal article)

Butt, N. M., McGinnity, N., & Clark, R. E. (2003). CD34 positive selection as prophylaxis against graft versus host disease in allogeneic peripheral blood stem cell transplantation.. Leukemia & lymphoma, 44(9), 1509-1513. doi:10.1080/1042819031000083019

DOI: 10.1080/1042819031000083019

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia (Journal article)

Olavarria, E., Ottmann, O. G., Deininger, M., Clark, R. E., Bandini, G., Byrne, J., . . . Fischer, T. (2003). Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia, 17(9), 1707-1712. doi:10.1038/sj.leu.2403068

DOI: 10.1038/sj.leu.2403068

A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). (Journal article)

Giles, F. J., Miller, C. B., Hurd, D. D., Wingard, J. R., Fleming, T. R., Sonis, S. T., . . . PROMPT-CT Trial Investigators. (2003). A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial).. Leukemia & lymphoma, 44(7), 1165-1172. doi:10.1080/1042819031000079159

DOI: 10.1080/1042819031000079159

CpG oligodeoxynucleotide 5mer-induced apoptosis in MOLT-4 leukaemia cells does not require caspase 3 or new protein synthesis (Journal article)

Tidd, D. M., Broughton, C. M., & Clark, R. E. (2003). CpG oligodeoxynucleotide 5mer-induced apoptosis in MOLT-4 leukaemia cells does not require caspase 3 or new protein synthesis. NUCLEIC ACIDS RESEARCH, 31(9), 2297-2304. doi:10.1093/nar/gkg334

DOI: 10.1093/nar/gkg334

A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. (Journal article)

Papas, A. S., Clark, R. E., Martuscelli, G., O'Loughlin, K. T., Johansen, E., & Miller, K. B. (2003). A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation.. Bone marrow transplantation, 31(8), 705-712. doi:10.1038/sj.bmt.1703870

DOI: 10.1038/sj.bmt.1703870

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. (Journal article)

Wang, L., Pearson, K., Ferguson, J. E., & Clark, R. E. (2003). The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.. British journal of haematology, 120(6), 990-999. doi:10.1046/j.1365-2141.2003.04200.x

DOI: 10.1046/j.1365-2141.2003.04200.x

Successful mobilisation of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukemia patients with imatinib mesylate (Gleevec®)-induced complete cytogenetic remission (Journal article)

Drummond, M. W., Marin, D., Clark, R. E., Byrne, J., Goldman, J. M., Holyoake, T. L., & Lennard, A. (2003). Successful mobilisation of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukemia patients with imatinib mesylate (Gleevec®)-induced complete cytogenetic remission. British Journal of Haematology, 123(3), 479-483.

2002

Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia. (Journal article)

Salim, R., Wang, L., Lin, K., & Clark, R. E. (2002). Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia.. Leukemia & lymphoma, 43(11), 2225-2227. doi:10.1080/1042819021000016140a

DOI: 10.1080/1042819021000016140a

Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia. (Journal article)

Wang, L., Pearson, K., Pillitteri, L., Ferguson, J. E., & Clark, R. E. (2002). Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.. British journal of haematology, 118(3), 771-777. doi:10.1046/j.1365-2141.2002.03705.x

DOI: 10.1046/j.1365-2141.2002.03705.x

The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase. (Journal article)

Olavarria, E., Reiffers, J., Boque, C., Sureda, A., Meloni, G., Michallet, M., . . . Apperley, J. F. (2002). The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase.. British journal of haematology, 118(3), 762-770. doi:10.1046/j.1365-2141.2002.03600.x

DOI: 10.1046/j.1365-2141.2002.03600.x

e19a2-positive chronic myeloid leukaemia with BCR exon e16-deleted transcripts. (Journal article)

Wang, L., Seale, J., Woodcock, B. E., & Clark, R. E. (2002). e19a2-positive chronic myeloid leukaemia with BCR exon e16-deleted transcripts.. Leukemia, 16(8), 1562-1563. doi:10.1038/sj.leu.2402600

DOI: 10.1038/sj.leu.2402600

Not so NICE for CML (Journal article)

Goldman, J., Apperley, J., Clark, R., Green, T., Holyoake, T., O'Brien, S., & Shepherd, P. (2002). Not so NICE for CML. LANCET, 359(9322), 2036. doi:10.1016/S0140-6736(02)08796-2

DOI: 10.1016/S0140-6736(02)08796-2

Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants. (Journal article)

Ljungman, P., de La Camara, R., Milpied, N., Volin, L., Russell, C. A., Crisp, A., . . . Valacyclovir International Bone Marrow Transplant Study Group. (2002). Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.. Blood, 99(8), 3050-3056. doi:10.1182/blood.v99.8.3050

DOI: 10.1182/blood.v99.8.3050

Bone turnover following autologous transplantation in multiple myeloma. (Journal article)

Clark, R. E., & Fraser, W. D. (2002). Bone turnover following autologous transplantation in multiple myeloma.. Leukemia & lymphoma, 43(3), 511-516. doi:10.1080/10428190290011985

DOI: 10.1080/10428190290011985

Position paper on imatinib mesylate in chronic myeloid leukaemia (Journal article)

O'Brien, S. G., Rule, S. A. J., Milligan, D. W., Johnson, S., Marcus, R., Goldman, J. M., . . . Smith, G. (2002). Position paper on imatinib mesylate in chronic myeloid leukaemia. British Journal of Haematology, 119, 268-272.

2001

Laparoscopically assisted splenectomy for idiopathic thrombocytopenic purpura in a previously conserved spleen. (Journal article)

Isherwood, P., Hershman, M. J., Hartley, M., & Clark, R. E. (2001). Laparoscopically assisted splenectomy for idiopathic thrombocytopenic purpura in a previously conserved spleen.. Hospital medicine (London, England : 1998), 62(11), 708-709.

Expression of c-myc is not critical for cell proliferation in established human leukemia lines. (Journal article)

Tidd, D. M., Giles, R. V., Broughton, C. M., & Clark, R. E. (2001). Expression of c-myc is not critical for cell proliferation in established human leukemia lines.. BMC molecular biology, 2, 13. doi:10.1186/1471-2199-2-13

DOI: 10.1186/1471-2199-2-13

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. (Journal article)

Clark, R. E., Dodi, I. A., Hill, S. C., Lill, J. R., Aubert, G., Macintyre, A. R., . . . Madrigal, J. A. (2001). Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.. Blood, 98(10), 2887-2893. doi:10.1182/blood.v98.10.2887

DOI: 10.1182/blood.v98.10.2887

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. (Journal article)

Goldstone, A. H., Burnett, A. K., Wheatley, K., Smith, A. G., Hutchinson, R. M., Clark, R. E., & Medical Research Council Adult Leukemia Working Party. (2001). Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial.. Blood, 98(5), 1302-1311. doi:10.1182/blood.v98.5.1302

DOI: 10.1182/blood.v98.5.1302

HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia. (Journal article)

Clark, R. E., Hermans, J., Madrigal, A., Nachbaur, D., Kropshofer, G., Gratwohl, A., . . . Chronic Leukaemia Working Party of the European Group of Blood and Bone Marrow Transplantation. (2001). HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia.. British journal of haematology, 114(1), 36-41. doi:10.1046/j.1365-2141.2001.02897.x

DOI: 10.1046/j.1365-2141.2001.02897.x

High frequency of positive surveillance for cytomegalovirus (CMV) by PCR in allograft recipients at low risk of CMV. (Journal article)

Butt, N. M., & Clark, R. E. (2001). High frequency of positive surveillance for cytomegalovirus (CMV) by PCR in allograft recipients at low risk of CMV.. Bone marrow transplantation, 27(6), 615-619. doi:10.1038/sj.bmt.1702836

DOI: 10.1038/sj.bmt.1702836

BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia. (Journal article)

Clark, R. E., & Christmas, S. E. (2001). BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia.. Leukemia & lymphoma, 42(5), 871-880. doi:10.3109/10428190109097706

DOI: 10.3109/10428190109097706

Characterisation of HLA-A3 restricted peptide from the BCR-ABL fusion protein of the Philadelphia chromosome using Nano-electrospray ion trap mass spectrometry (Journal article)

Creaser, C. S., Lill, J. R., Bonner, P. L. R., Hill, S. C., Rees, R. C., Christmas, S. E., . . . Madrigal, J. A. (2001). Characterisation of HLA-A3 restricted peptide from the BCR-ABL fusion protein of the Philadelphia chromosome using Nano-electrospray ion trap mass spectrometry. Advances in Mass Spectrometry, 15, 637-638.

Expression of c-myc is not critical for cell proliferation in established human leukemia lines (Journal article)

Tidd, D. M., Giles, R. V., Broughton, C. M., & Clark, R. E. (2001). Expression of c-myc is not critical for cell proliferation in established human leukemia lines. Biomed Central (BMC) Molecular Biology, 2, 13. Retrieved from http://www.biomedcentral.com/1471-2199/2/13/

2000

Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. (Journal article)

Clark, R. E., Flory, A. J., Ion, E. M., Woodcock, B. E., Durham, B. H., & Fraser, W. D. (2000). Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma.. Blood, 96(8), 2697-2702.

b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. (Journal article)

Norbury, L. C., Clark, R. E., Christmas, S. E., & Christmas, S. E. (2000). b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia.. British journal of haematology, 109(3), 616-621. doi:10.1046/j.1365-2141.2000.02090.x

DOI: 10.1046/j.1365-2141.2000.02090.x

Oligodeoxynucleotide 5mers containing a 5′-CpG induce apoptosis through a mitochondrial mechanism in T lymphocytic leukaemia cells (Journal article)

Tidd, D. M., Spiller, D. G., Broughton, C. M., Norbury, L. C., Clark, R. E., & Giles, R. V. (2000). Oligodeoxynucleotide 5mers containing a 5′-CpG induce apoptosis through a mitochondrial mechanism in T lymphocytic leukaemia cells. NUCLEIC ACIDS RESEARCH, 28(11), 2242-2250. doi:10.1093/nar/28.11.2242

DOI: 10.1093/nar/28.11.2242

Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems. (Journal article)

Clark, R. E. (2000). Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems.. Leukemia, 14(3), 347-355. doi:10.1038/sj.leu.2401677

DOI: 10.1038/sj.leu.2401677

1999

Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia (Journal article)

Clark, R. E., Grzybowski, J., Broughton, C. M., Pender, N. T., Spiller, D. G., Brammer, C. G., . . . Tidd, D. M. (1999). Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia. BONE MARROW TRANSPLANTATION, 23(12), 1303-1308. doi:10.1038/sj.bmt.1701801

DOI: 10.1038/sj.bmt.1701801

Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA. (Journal article)

Giles, R. V., Spiller, D. G., Clark, R. E., & Tidd, D. M. (1999). Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA.. Antisense & nucleic acid drug development, 9(2), 213-220. doi:10.1089/oli.1.1999.9.213

DOI: 10.1089/oli.1.1999.9.213

Antisense morpholino oligonucleotide analogue induces mis-splicing of c-MYC mRNA (Journal article)

Giles, R. V., Spiller, D. G., Clark, R. E., & Tidd, D. M. (1999). Antisense morpholino oligonucleotide analogue induces mis-splicing of c-MYC mRNA. Antisense & Nucleic Acid Drug Development, 9, 213-220.

Chemotherapy-induced acral erythema (CIAE) with bullous reaction (Journal article)

Azurdia, R. M., Clark, R. E., & Friedmann, P. S. (1999). Chemotherapy-induced acral erythema (CIAE) with bullous reaction. Clinical and Experimental Dermatology, 24, 64-66.

Identification of a good c-myc antisense oligodeoxynucleotide target site and the inactivity at this site of novel NCH triplet--targeting ribozymes. (Journal article)

Giles, R. V., Spiller, D. G., Clark, R. E., & Tidd, D. M. (1999). Identification of a good c-myc antisense oligodeoxynucleotide target site and the inactivity at this site of novel NCH triplet--targeting ribozymes.. Nucleosides & nucleotides, 18(9), 1935-1944. doi:10.1080/07328319908044855

DOI: 10.1080/07328319908044855

1998

Bone-marrow donation by mentally incapable adults. (Journal article)

Clark, R. E. (1998). Bone-marrow donation by mentally incapable adults.. Lancet (London, England), 352(9143), 1847-1848. doi:10.1016/s0140-6736(98)04378-5

DOI: 10.1016/s0140-6736(98)04378-5

Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. (Journal article)

Clark, R. E., & Brammer, C. G. (1998). Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system.. Bone marrow transplantation, 22(9), 859-863. doi:10.1038/sj.bmt.1701461

DOI: 10.1038/sj.bmt.1701461

Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells. (Journal article)

Singer, I. O., Franklin, I. M., Clark, R. E., Chalmers, E. A., Kelsey, S. M., Newland, A. C., . . . Tansey, P. J. (1998). Autologous transplantation in chronic myeloid leukaemia using peripheral blood stem cells.. British journal of haematology, 102(5), 1359-1362. doi:10.1046/j.1365-2141.1998.00897.x

DOI: 10.1046/j.1365-2141.1998.00897.x

Comparison of a patient-controlled analgesia system with continuous infusion for administration of diamorphine for mucositis. (Journal article)

Pillitteri, L. C., & Clark, R. E. (1998). Comparison of a patient-controlled analgesia system with continuous infusion for administration of diamorphine for mucositis.. Bone marrow transplantation, 22(5), 495-498. doi:10.1038/sj.bmt.1701370

DOI: 10.1038/sj.bmt.1701370

Abnormalities of the ETV6 gene occur in the majority of patients with aberrations of the short arm of chromosome 12: a combined PCR and Southern blotting analysis. (Journal article)

O'Connor, H. E., Butler, T. A., Clark, R., Swanton, S., Harrison, C. J., Secker-Walker, L. M., & Foroni, L. (1998). Abnormalities of the ETV6 gene occur in the majority of patients with aberrations of the short arm of chromosome 12: a combined PCR and Southern blotting analysis.. Leukemia, 12(7), 1099-1106. doi:10.1038/sj.leu.2401070

DOI: 10.1038/sj.leu.2401070

Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation. (Journal article)

Spiller, D. G., Giles, R. V., Grzybowski, J., Tidd, D. M., & Clark, R. E. (1998). Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation.. Blood, 91(12), 4738-4746.

Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells. (Journal article)

Giles, R. V., Spiller, D. G., Grzybowski, J., Clark, R. E., Nicklin, P., & Tidd, D. M. (1998). Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells.. Nucleic acids research, 26(7), 1567-1575. doi:10.1093/nar/26.7.1567

DOI: 10.1093/nar/26.7.1567

Maximising antisense oligonucleotide efficacy: Selecting optimal structures for Streptolysin O delivery into human leukaemia cells (Journal article)

Giles, R. V., Spiller, D. G., Grzybowski, J., Clark, R. E., Nicklin, P., & Tidd, D. M. (1998). Maximising antisense oligonucleotide efficacy: Selecting optimal structures for Streptolysin O delivery into human leukaemia cells. Nucleic Acids Research, 26, 1567-1575.

The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses (Journal article)

Spiller, D. G., Giles, R. V., Broughton, C. M., Grzybowski, J., Ruddell, C. J., Tidd, D. M., & Clark, R. E. (1998). The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses. ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 8(4), 281-293. doi:10.1089/oli.1.1998.8.281

DOI: 10.1089/oli.1.1998.8.281

1997

Improving the molecular efficacy of antisense oligonucleotider (ODN) in chronic myeloid leukaemia (Journal article)

Clark, R. E., Grjsybowski, J., Giles, R. V., Spiller, D. G., & Tidd, D. M. (1997). Improving the molecular efficacy of antisense oligonucleotider (ODN) in chronic myeloid leukaemia. Experimental Hematology, 25(8), 892.

Transplantation of antisense oligonucleotide (odn) purged autografts in chronic myeloid leukaemia (cml) (Journal article)

Clark, R. E. (1997). Transplantation of antisense oligonucleotide (odn) purged autografts in chronic myeloid leukaemia (cml). Experimental Hematology, 25(8), 781.

Preclinical studies of streptolysin-O in enhancing antisense oligonucleotide uptake in harvests from chronic myeloid leukaemia patients (Journal article)

Broughton, C. M., Spiller, D. G., Pender, N., Komorovskaya, M., Grzybowski, J., Giles, R. V., . . . Clark, R. E. (1997). Preclinical studies of streptolysin-O in enhancing antisense oligonucleotide uptake in harvests from chronic myeloid leukaemia patients. LEUKEMIA, 11(9), 1435-1441. doi:10.1038/sj.leu.2400774

DOI: 10.1038/sj.leu.2400774

European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. (Journal article)

Devergie, A., Apperley, J. F., Labopin, M., Madrigal, A., Jacobsen, N., Carreras, E., . . . Gratwohl, A. (1997). European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.. Bone marrow transplantation, 20(1), 11-19. doi:10.1038/sj.bmt.1700844

DOI: 10.1038/sj.bmt.1700844

Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia (Journal article)

Broughton, C. M., Sherrington, P., Pender, N. T., & Clark, R. E. (1997). Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia. GENES CHROMOSOMES & CANCER, 18(4), 292-298. doi:3.0.CO;2-W">10.1002/(SICI)1098-2264(199704)18:4<292::AID-GCC7>3.0.CO;2-W

DOI: 10.1002/(SICI)1098-2264(199704)18:4<292::AID-GCC7>3.0.CO;2-W

Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia. (Journal article)

Broughton, C. M., Sherrington, P., Pender, N. T., & Clark, R. E. (1997). Molecular status of individual CFU-GM colonies derived from chemotherapy-mobilised peripheral blood stem cells in chronic myeloid leukaemia.. Genes, chromosomes & cancer, 18(4), 292-298. doi:3.0.co;2-w">10.1002/(sici)1098-2264(199704)18:4<292::aid-gcc7>3.0.co;2-w

DOI: 10.1002/(sici)1098-2264(199704)18:4<292::aid-gcc7>3.0.co;2-w

Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia-negative peripheral blood stem cells. (Journal article)

Chalmers, E. A., Franklin, I. M., Kelsey, S. M., Newland, A. C., Clark, R. E., Sproul, A. M., . . . Tansey, P. (1997). Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia-negative peripheral blood stem cells.. British journal of haematology, 96(3), 627-634. doi:10.1046/j.1365-2141.1997.d01-2058.x

DOI: 10.1046/j.1365-2141.1997.d01-2058.x

Bone marrow effects of anticancer therapy (Chapter)

Clark, R. E. (1997). Bone marrow effects of anticancer therapy. In J. W. Sweetenham, & C. J. Williams (Eds.), Supportive care of the cancer patient (pp. 3-15). London: Edward Arnold.

Stem cell transplantation (Chapter)

Clark, R. E. (1997). Stem cell transplantation. In F. E. Johnson, & K. S. Virgo (Eds.), Cancer patient follow-up (pp. 504-507). St Louis: Mosby Inc..

The follow-up of patients with lymphoma (Chapter)

Clark, R. E. (1997). The follow-up of patients with lymphoma. In F. E. Johnson, & K. S. Virgo (Eds.), Cancer patient follow-up (pp. 480-483). St Louis: Mosby Inc..

1996

The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide. (Journal article)

MacIntyre, A. R., Christmas, S. E., & Clark, R. E. (1996). The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide.. Experimental hematology, 24(11), 1307-1311.

1995

Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA. (Journal article)

Giles, R. V., Spiller, D. G., Green, J. A., Clark, R. E., & Tidd, D. M. (1995). Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA.. Blood, 86(2), 744-754.

FMS mutations in patients following cytotoxic therapy for lymphoma (Journal article)

Baker, A., Cachia, P. G., Ridge, S. A., McGlynn, H., Clark, R. E., Whittaker, J. A., . . . Padua, R. A. (1995). FMS mutations in patients following cytotoxic therapy for lymphoma. Leukaemia Research, 19, 309-318.

Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia. (Journal article)

Clark, R. E. (1995). Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia.. Leukemia & lymphoma, 19(3-4), 189-195. doi:10.3109/10428199509107888

DOI: 10.3109/10428199509107888

Psychosocial morbidity following bone marrow transplantation is related to previous experience of intensive therapy (Journal article)

Leigh, S., Burns, R., Wilson, K., & Clark, R. E. (1995). Psychosocial morbidity following bone marrow transplantation is related to previous experience of intensive therapy. Bone Marrow Transplantation, 13, 635-640.

Psychosocial morbidity in bone marrow transplant recipients: a prospective study. (Journal article)

Leigh, S., Wilson, K. C., Burns, R., & Clark, R. E. (1995). Psychosocial morbidity in bone marrow transplant recipients: a prospective study.. Bone marrow transplantation, 16(5), 635-640.

Severe hypophosphataemia during stem cell harvesting in chronic myeloid leukaemia. (Journal article)

Clark, R. E., & Lee, E. S. (1995). Severe hypophosphataemia during stem cell harvesting in chronic myeloid leukaemia.. British journal of haematology, 90(2), 450-452. doi:10.1111/j.1365-2141.1995.tb05172.x

DOI: 10.1111/j.1365-2141.1995.tb05172.x

Transplantation of T-lymphocyte depleted marrow with an addback of T cells. (Journal article)

Clark, R. E., & Pender, N. (1995). Transplantation of T-lymphocyte depleted marrow with an addback of T cells.. Hematological oncology, 13(4), 219-224. doi:10.1002/hon.2900130406

DOI: 10.1002/hon.2900130406

Transplantation of T-lymphocyte depleted marrow with an addback of T cells: Control of graft-versus-host disease with a high relapse rate (Journal article)

Clark, R. E., & Pender, N. (1995). Transplantation of T-lymphocyte depleted marrow with an addback of T cells: Control of graft-versus-host disease with a high relapse rate. Haematological Oncology, 13, 219-224.

1994

Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective. (Journal article)

Clark, R. E., Shlebak, A. A., & Creagh, M. D. (1994). Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective.. Leukemia & lymphoma, 16(1-2), 141-146. doi:10.3109/10428199409114151

DOI: 10.3109/10428199409114151

Mobilisation of Ph-negative peripheral blood stem cells in CML with Idarubicin and Cytarabine (Journal article)

Chalmers, E. A., Franklin, I. M., Kelsey, S., Clark, R. E., Sproul, A. M., Goldstone, A. H., . . . Tansey, P. (1994). Mobilisation of Ph-negative peripheral blood stem cells in CML with Idarubicin and Cytarabine. Bone Marrow Transplantation, 14, Su, 38-41.

The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project. (Journal article)

Mamounas, E. P., Anderson, S., Wickerham, D. L., Clark, R., Stoller, R., Hamm, J. T., . . . Bornstein, R. (1994). The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.. American journal of clinical oncology, 17(5), 374-382. doi:10.1097/00000421-199410000-00002

DOI: 10.1097/00000421-199410000-00002

Thrombotic microangiopathy following bone marrow transplantation. (Journal article)

Pettitt, A. R., & Clark, R. E. (1994). Thrombotic microangiopathy following bone marrow transplantation.. Bone marrow transplantation, 14(4), 495-504.

Vogt-Koyanagi-Harada syndrome complicating allogeneic bone marrow transplantation. (Journal article)

Pettitt, A. R., Neoh, C., Wong, S. H., & Clark, R. E. (1994). Vogt-Koyanagi-Harada syndrome complicating allogeneic bone marrow transplantation.. Bone marrow transplantation, 13(2), 225-227.

1993

Clonal haemopoiesis following cytotoxic therapy for lymphoma. (Journal article)

Cachia, P. G., Culligan, D. J., Clark, R. E., Whittaker, J. A., Jacobs, A., & Padua, R. A. (1993). Clonal haemopoiesis following cytotoxic therapy for lymphoma.. Leukemia, 7(6), 795-800.

Long-term bone marrow cultures established from bone marrow transplant recipients. (Journal article)

Treweeke, A. T., Hampson, J., & Clark, R. E. (1993). Long-term bone marrow cultures established from bone marrow transplant recipients.. Leukemia & lymphoma, 12(1-2), 117-122. doi:10.3109/10428199309059579

DOI: 10.3109/10428199309059579

1992

Chromosome aberrations following cytotoxic therapy in patients in complete remission from lymphoma. (Journal article)

White, A. D., Jones, B. M., Clark, R. E., & Jacobs, A. (1992). Chromosome aberrations following cytotoxic therapy in patients in complete remission from lymphoma.. Carcinogenesis, 13(7), 1095-1099. doi:10.1093/carcin/13.7.1095

DOI: 10.1093/carcin/13.7.1095

Thrombotic thrombocytopenic purpura due to rifampicin. (Journal article)

Fahal, I. H., Williams, P. S., Clark, R. E., & Bell, G. M. (1992). Thrombotic thrombocytopenic purpura due to rifampicin.. BMJ (Clinical research ed.), 304(6831), 882. doi:10.1136/bmj.304.6831.882

DOI: 10.1136/bmj.304.6831.882

Isochromosome (6p) in Waldenstrom's macroglobulinemia. (Journal article)

White, A. D., Clark, R. E., & Jacobs, A. (1992). Isochromosome (6p) in Waldenstrom's macroglobulinemia.. Cancer genetics and cytogenetics, 58(1), 89-91. doi:10.1016/0165-4608(92)90141-t

DOI: 10.1016/0165-4608(92)90141-t

1990

Haemopoietic and molecular abnormalities in the myelodysplastic syndrome (Chapter)

Jacobs, A., Carter, G., Ridge, S., Hughes, D., Geddes, D., Bowen, D., . . . Padua, R. A. (1990). Haemopoietic and molecular abnormalities in the myelodysplastic syndrome. In L. Sachs (Ed.), Molecular Biology of Haemopoiesis (pp. 571-577). Andover UK: Intercept Ltd.

RAS mutations in patients following cytotoxic therapy for lymphoma. (Journal article)

Carter, G., Hughes, D. C., Clark, R. E., McCormick, F., Jacobs, A., Whittaker, J. A., & Padua, R. A. (1990). RAS mutations in patients following cytotoxic therapy for lymphoma.. Oncogene, 5(3), 411-416.

1989

Differences in bone marrow cytogenetic characteristics between treated and untreated myeloma. (Journal article)

Clark, R. E., Geddes, A. D., Whittaker, J. A., & Jacobs, A. (1989). Differences in bone marrow cytogenetic characteristics between treated and untreated myeloma.. European journal of cancer & clinical oncology, 25(12), 1789-1793. doi:10.1016/0277-5379(89)90349-0

DOI: 10.1016/0277-5379(89)90349-0

Posttransplantation diabetes mellitus in heart transplant recipients. (Journal article)

Ladowski, J. S., Kormos, R. L., Uretsky, B. F., Lee, A., Curran, M., Clark, R., . . . Hardesty, R. L. (1989). Posttransplantation diabetes mellitus in heart transplant recipients.. The Journal of heart transplantation, 8(2), 181-183.

RAS mutations detected by PCR and specific oligonucleotide hybridisation in preleukaemia (Journal article)

Carter, G., Padua, R. A., Hughes, D. C., McCormick, F., Oscier, D., Clark, R. E., . . . Jacobs, A. (1989). RAS mutations detected by PCR and specific oligonucleotide hybridisation in preleukaemia. Cancer Cells, 7, 143-145.

RAS oncogenes (Chapter)

Jacobs, A., Padua, R. A., Carter, G., Hughes, D., Clark, R. E., Oscier, D., . . . McCormick, F. (1989). RAS oncogenes. In D. Spandidos (Ed.), RAS oncogenes (Vol. 170, pp. 1-100). New York: Plenum Press.

1988

13-cis-retinoic acid v placebo in myelodysplasia. (Journal article)

Jacobs, A., & Clark, R. E. (1988). 13-cis-retinoic acid v placebo in myelodysplasia.. Blood, 72(4), 1439-1440.

Myelodysplastic syndrome in a kindred with ins(16) (p11.2). (Journal article)

Clark, R. E., Geddes, D., Whittaker, K., & Jacobs, A. (1988). Myelodysplastic syndrome in a kindred with ins(16) (p11.2).. Clinical genetics, 33(6), 418-423. doi:10.1111/j.1399-0004.1988.tb03474.x

DOI: 10.1111/j.1399-0004.1988.tb03474.x

Myelodysplastic syndrome in a kindred with ins(16)(p11.2) (Journal article)

Clark, R. E., Geddes, D., Whittaker, K., & Jacobs, A. (1988). Myelodysplastic syndrome in a kindred with ins(16)(p11.2). Clinical Genetics, 33, 417-422.

1987

Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid. (Journal article)

Clark, R. E., Smith, S. A., & Jacobs, A. (1987). Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid.. Journal of clinical pathology, 40(6), 652-656. doi:10.1136/jcp.40.6.652

DOI: 10.1136/jcp.40.6.652

Primary myelodysplastic syndrome and cancer. (Journal article)

Clark, R. E., Payne, H. E., Jacobs, A., & West, R. R. (1987). Primary myelodysplastic syndrome and cancer.. British medical journal (Clinical research ed.), 294(6577), 937-938. doi:10.1136/bmj.294.6577.937-a

DOI: 10.1136/bmj.294.6577.937-a

Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. (Journal article)

Clark, R. E., Jacobs, A., Lush, C. J., & Smith, S. A. (1987). Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome.. Lancet (London, England), 1(8536), 763-765. doi:10.1016/s0140-6736(87)92796-6

DOI: 10.1016/s0140-6736(87)92796-6

A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome. (Journal article)

Clark, R. E., Ismail, S. A., Jacobs, A., Payne, H., & Smith, S. A. (1987). A randomized trial of 13-cis retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome.. British journal of haematology, 66(1), 77-83. doi:10.1111/j.1365-2141.1987.tb06893.x

DOI: 10.1111/j.1365-2141.1987.tb06893.x

The effect of cytosine arabinoside on CFU-GM from patients with myelodysplastic syndrome. (Journal article)

Bailey-Wood, R., Clark, R. E., Dallimore, C. M., & Jacobs, A. (1987). The effect of cytosine arabinoside on CFU-GM from patients with myelodysplastic syndrome.. Clinical and laboratory haematology, 9(1), 23-26. doi:10.1111/j.1365-2257.1987.tb01378.x

DOI: 10.1111/j.1365-2257.1987.tb01378.x

1986

Prognostic Importance of Hypodiploid Hemopoietic Precursors in Myelodysplastic Syndromes (Journal article)

Clark, R., Peters, S., Hoy, T., Smith, S., Whittaker, K., & Jacobs, A. (1986). Prognostic Importance of Hypodiploid Hemopoietic Precursors in Myelodysplastic Syndromes. New England Journal of Medicine, 314(23), 1472-1475. doi:10.1056/nejm198606053142302

DOI: 10.1056/nejm198606053142302

DNA content and cell cycle analysis of bone marrow cells in myelodysplastic syndromes (MDS). (Journal article)

Peters, S. W., Clark, R. E., Hoy, T. G., & Jacobs, A. (1986). DNA content and cell cycle analysis of bone marrow cells in myelodysplastic syndromes (MDS).. British journal of haematology, 62(2), 239-245. doi:10.1111/j.1365-2141.1986.tb02927.x

DOI: 10.1111/j.1365-2141.1986.tb02927.x

Pathogenesis and clinical variations in the myelodysplastic syndromes (Journal article)

Jacobs, A., & Clark, R. E. (1986). Pathogenesis and clinical variations in the myelodysplastic syndromes. Clinics in Haematology, 15, 925-952.

Pathogenesis and clinical variations in the myelodysplastic syndromes. (Journal article)

Jacobs, A., & Clark, R. E. (1986). Pathogenesis and clinical variations in the myelodysplastic syndromes.. Clinics in haematology, 15(4), 925-951.

1985

Granulocyte and monocyte surface membrane markers in the myelodysplastic syndromes. (Journal article)

Clark, R. E., Hoy, T. G., & Jacobs, A. (1985). Granulocyte and monocyte surface membrane markers in the myelodysplastic syndromes.. Journal of clinical pathology, 38(3), 301-304. doi:10.1136/jcp.38.3.301

DOI: 10.1136/jcp.38.3.301